



**ANNUAL INFORMATION FORM**  
**FOR THE YEAR ENDED DECEMBER 31, 2024**

**March 26, 2025**

## TABLE OF CONTENTS

NOTE TO READER .....	3
GLOSSARY OF TERMS.....	3
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS.....	5
CORPORATE STRUCTURE .....	7
GENERAL DEVELOPMENT OF THE BUSINESS.....	9
DESCRIPTION OF THE BUSINESS.....	11
RISK FACTORS .....	17
DIVIDENDS .....	27
DESCRIPTION OF CAPITAL STRUCTURE .....	27
MARKET FOR SECURITIES.....	30
ESCROWED SECURITIES AND SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER .....	31
DIRECTORS AND OFFICERS.....	31
LEGAL PROCEEDINGS AND REGULATORY ACTIONS .....	34
INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS.....	34
INTEREST OF EXPERTS .....	34
TRANSFER AGENT .....	34
MATERIAL CONTRACTS.....	34
AUDIT COMMITTEE INFORMATION .....	34
ADDITIONAL INFORMATION.....	36
APPENDIX A – AUDIT COMMITTEE CHARTER .....	A-1

## NOTE TO READER

The information in this Annual Information Form dated March 26, 2025 for the fiscal year ended December 31, 2024 (this “AIF”) is stated as of December 31, 2024 unless otherwise indicated. All dollar amounts are expressed in Canadian dollars unless otherwise indicated.

This AIF contains forward-looking statements based on NeuPath Health Inc.’s (the “Corporation” or “NeuPath”) current expectations, activities and beliefs. Such information involves a number of known and unknown risks and uncertainties, including those discussed in this AIF under the heading entitled “Risk Factors”. See “Cautionary Statement Regarding Forward-Looking Statements”.

## GLOSSARY OF TERMS

Capitalized terms used, but not otherwise defined in this AIF, having the meanings set out below. Words importing the singular, where the context requires, include the plural and vice versa and words importing any gender include all genders.

“**2025 Revolving Facility**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**2025 Term Loan**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**2276321**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**257**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**Acquisition Line**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**AIM Hamilton**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**AIM Health**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**Amalco**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**Arrangement**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**Audit Committee**” means the audit committee of the Board.

“**Board**” means the board of directors of the Corporation.

“**Broker Warrants**” means warrants of the Corporation issued to brokers in connection with the Offering, as more fully described under the heading “*Description of Capital Structure – Description of Warrants*”.

“**Common Shares**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**CompreMed**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**Corporation**” or “**NeuPath**” has the meaning ascribed thereto under the heading “*Note to Reader*”.

“**CRA**” means Canada Revenue Agency.

“**Debentures**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Subordinated and Postponed Unsecured Non-convertible Debentures*”.

“**Delegated Authority**” has the meaning ascribed thereto under the heading “*Audit Committee Information – Pre-Approval Policies and Procedures*”.

“**Haywood**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Normal Course Issuer Bid*”.

“**HealthPointe**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**HealthPointe@CAO**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**HST**” means Harmonized Sales Tax.

“**InMedic**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**KumoCare**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**National Bank**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**NBC Credit Agreement**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**NBC Credit Facilities**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – March 26, 2025)*”.

“**New Policy**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Stock Options*”.

“**NI 51-102**” means National Instrument 51-102 – *Continuous Disclosure Obligations*.

“**NCIB**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2024 (January 1, 2024 – December 31, 2024)*”.

“**OBCA**” means the *Business Corporations Act* (Ontario) as in effect as of the date of this AIF.

“**Offering**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2023 (January 1, 2023 – December 31, 2023)*”.

“**Prefunded Warrants**” means the prefunded Common Share purchase warrants of the Corporation issued in exchange for prefunded common share purchase warrants of 257 pursuant to the Qualifying Transaction.

“**QT Warrants**” means the Common Share purchase warrants of the Corporation issued in exchange for common share purchase warrants of 257 pursuant to the Qualifying Transaction.

“**Qualifying Transaction**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**Redemption Date**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – December 31, 2025)*”.

“**RBC**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2023 (January 1, 2023 – December 31, 2023)*”.

“**RBC Credit Facility**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2023 (January 1, 2023 – December 31, 2023)*”.

“**Renaissance**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**RSU Plan**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Restricted Share Units*”.

“**RSUs**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Restricted Share Units*”.

“**Stock Option Plan**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Stock Options*”.

“**Stock Options**” has the meaning ascribed thereto under the heading “*Description of Capital Structure – Description of Stock Options*”.

“**Subco**” has the meaning ascribed thereto under the heading “*Corporate Structure – General*”.

“**Task Force**” has the meaning ascribed thereto under the heading “*General Development of Business – Chronic Pain*”.

“**Total Redemption Price**” has the meaning ascribed thereto under the heading “*General Development of Business – Fiscal 2025 (January 1, 2025 – December 31, 2025)*”.

“**TSXV**” means the TSX Venture Exchange.

“**Units**” has the meaning ascribed thereto under the heading “*General Development of Business - Fiscal 2023 (January 1, 2023 – December 31, 2023)*”.

“**Viable Clinic**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

“**Viable Healthworks**” has the meaning ascribed thereto under the heading “*Corporation Structure – Intercorporate Relationships*”.

#### **CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This AIF may contain or incorporate by reference information that constitutes “forward-looking information” or “forward-looking statements” (collectively, “**forward-looking information**”) within the meaning of applicable securities legislation, which involves known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the Corporation or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. When used in this AIF, such information uses words such as “may,” “will,” “expect,” “believe,” “plan,” “intend” and other similar terminology. Forward-looking information contained herein reflects current expectations regarding future events and operating performance and speaks only as of the date of this AIF.

Forward-looking information involves significant risks and uncertainties, and therefore, should not be read as a guarantee of future performance or results and will not necessarily be an accurate indication of whether or not such results will be achieved. Accordingly, undue reliance should not be placed on such statements. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking information, including, but not limited to, the factors discussed in this AIF under the heading entitled “Risk Factors”. Some of these risks and assumptions include, among others:

- risks associated with government regulation and funding, and obtaining and maintaining the necessary permits and licences related to the business;
- recruitment and retention of physicians, and reliance on healthcare professionals;
- the sufficiency of the Corporation’s working capital, anticipated operating cash flow or its ability to raise additional funds on satisfactory terms;
- increasing competition in the market;

- the estimated cost and availability of funding for ongoing capital requirements;
- failure to achieve desired results in labour negotiations, including the terms of a future collective bargaining agreement;
- the Corporation's ability to successfully execute on its growth and expansion plans;
- compliance with environmental, health, safety and other laws and regulations; and
- whether the key personnel will continue their employment with the Corporation,

all are further and more fully described under the heading "Risk Factors" in this AIF.

All forward-looking information reflects the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Some of these material factors and assumptions include, among others:

- the Corporation is able to obtain future capital or additional financings as and when required on satisfactory terms;
- there being no material variations in the legislation and regulation of health care and health care professionals in Canada and the regulation of electronic medical records as it affects the business of the Corporation;
- that key personnel will continue with the Corporation; and
- the operating expenses, including general and administrative expenses, will continue in accordance with the management's expectation.

Forward-looking information is not based on historical facts but rather on management's expectations regarding future activities, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Although the forward-looking information contained in this AIF is based upon what management of the Corporation believes are reasonable assumptions, the Corporation cannot assure readers that actual results will be consistent with the forward-looking information.

Any forward-looking information represents the Corporation's estimates only as of the date of this AIF and should not be relied upon as representing the Corporation's estimates as of any subsequent date. The Corporation undertakes no obligation to update any forward-looking information to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events, except as may be required by securities legislation.

This AIF also includes market data and forecasts with respect to the chronic pain, sports medicine, concussion, and workplace health services markets. Although the Corporation is responsible for all of the disclosure contained in this AIF, in some cases the Corporation relies on and refers to market data and certain industry forecasts that were obtained from third party surveys, market research, consultant surveys, publicly available information and industry publications and surveys that it believes to be reliable. Unless otherwise indicated, all market and industry data and other statistical information and forecasts contained in this AIF are based on independent industry publications, reports by market research firms or other published independent sources and other externally obtained data that the Corporation believes to be reliable. Any such market data, information or forecast may prove to be inaccurate because of the method by which it was obtained or because it cannot always be verified with complete certainty given the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties, including those discussed in this AIF under the heading "Risk Factors". As a result, although the Corporation believes that these sources are reliable, it has not independently verified the information.

All references in this AIF to "the Corporation" refer to NeuPath Health Inc. and the subsidiaries through which it conducts its business, unless otherwise indicated.

## CORPORATE STRUCTURE

### General

The Corporation was incorporated pursuant to the provisions of the OBCA on April 17, 2019 under the name “Klinik Health Ventures Corp.”. The Corporation completed its initial public offering on December 3, 2019 and was listed on the TSXV as a capital pool company until it completed an arm’s length qualifying transaction on June 25, 2020 in accordance with the policies of the TSXV (the “**Qualifying Transaction**”). As a capital pool company, the Corporation had no assets other than cash and did not carry on any operations.

The Corporation’s Qualifying Transaction was structured as a reverse take-over by way of a statutory plan of arrangement under Section 182 of the OBCA, (the “**Arrangement**”) involving a wholly owned subsidiary of the Corporation, 2752695 Ontario Inc., (“**Subco**”) and a private Ontario corporation, 2576560 Ontario Inc. (“**257**”). Under the Arrangement, 257 amalgamated with Subco to form 5033421 Ontario Inc. (“**Amalco**”) and all of the issued and outstanding securities of 257 were exchanged for equivalent securities of the Corporation based on an exchange ratio of five (5) Common Shares (prior to giving effect to the consolidation described below) for each one (1) common share of 257 held prior to the completion of the Qualifying Transaction. As a consequence of the Arrangement, Amalco became a wholly owned subsidiary of the Corporation and the business and activities of 257 became the business of the Corporation. Immediately following the completion of the Arrangement, the Corporation changed its name to “NeuPath Health Inc.” and completed a share consolidation on a one-for-five basis.


On July 6, 2020, the common shares (the “**Common Shares**”) of the Corporation, which were previously halted on March 20, 2020, as a result of the announcement of the Qualifying Transaction, resumed trading on the TSXV under the ticker symbol “NPTH”.

The Corporation’s head office is located at 110 Matheson Blvd W, Suite 110, Mississauga, ON L5R 4G7 and its registered office is located at 181 Bay Street, Suite 2100, Toronto, Ontario, Canada.

The Corporation’s website is [www.neupath.com](http://www.neupath.com).

## Intercorporate Relationships

The following chart illustrates the subsidiaries of the Corporation, together with their respective jurisdictions of existence and share ownership as of the date of this AIF.



### Notes:

- (1) Amalco was formed pursuant to the amalgamation of Subco and 257 on June 25, 2020 in connection with the Arrangement.
- (2) Viable Healthworks (Canada) Corp. (“**Viable Healthworks**”) was incorporated pursuant to the *Business Corporations Act* (British Columbia) on January 12, 2009. Viable Healthworks and its subsidiaries were acquired by 257 on May 26, 2017.
- (3) CompreMed Canada Inc. (“**CompreMed**”) was incorporated pursuant to the OBCA on October 3, 2002. CompreMed operates an independent medical assessment business. CompreMed was acquired by 257 on March 31, 2019.
- (4) Renaissance Asset Management (London) Inc. (“**Renaissance**”) was incorporated pursuant to the OBCA on January 23, 2013. Renaissance and its subsidiaries were acquired by 257 on February 26, 2018.
- (5) AIM Health Group Corp. (“**AIM Health**”) was incorporated pursuant to the OBCA on November 12, 2009. AIM Health operates NeuPath Centre for Pain & Spine, the pain clinic business and a health staffing business that provides physician staffing to correctional facilities.
- (6) 2276321 Ontario Inc. (“**2276321**”) was incorporated pursuant to the OBCA on March 2, 2011. 2276321 is a real estate holding company that owned a building in London, Ontario that was sold on August 31, 2023. The InMedic headquarters and the London medical clinic which previously occupied the building have been relocated to a new facility in London, Ontario.
- (7) Viable Clinic Research Corp. (“**Viable Clinic**”) was incorporated pursuant to the OBCA on December 10, 2009. Viable Clinic is a contract research business.
- (8) InMedic Corporation (“**InMedic**”) was incorporated pursuant to the OBCA on January 19, 2011. InMedic is an operating entity for the Corporation’s pain clinic business.
- (9) Accident Injury Management Clinic (Hamilton-Rosedale) Inc. (“**AIM Hamilton**”) was incorporated pursuant to the OBCA on December 2, 2009. AIM Hamilton owns and operates a chronic pain management clinic in Hamilton, Ontario.
- (10) Healthpointe Medical Centres Ltd. (“**HealthPointe**”) was incorporated pursuant to the *Business Corporations Act* (Alberta) on February 26, 2007. HealthPointe was acquired by the Corporation on February 7, 2021. HealthPointe operates a pain, spine and sport medicine clinic in Edmonton, Alberta.



- (11) Aidly, Inc. (“**KumoCare**”) was formed pursuant to an amalgamation of Aidly Inc. and KumoCare Peel York Inc. on July 23, 2021. KumoCare was acquired by the Corporation on August 16, 2021. KumoCare’s proprietary virtual care platform allows physicians, personal support workers and allied health providers to see patients via telemedicine and in-home.
- (12) HealthPointe@CAO Services Ltd. (“**HealthPointe@CAO**”) was incorporated pursuant to the *Business Corporations Act* (Alberta) on September 22, 2021.

## GENERAL DEVELOPMENT OF THE BUSINESS

### Fiscal 2025 (January 1, 2025 - March 26, 2025)

On March 26, 2025, the Corporation entered into a new credit agreement (the “**NBC Credit Agreement**”) with the National Bank of Canada (“**National Bank**”). This arrangement provides up to \$13.5 million to execute NeuPath’s growth plan and refinance existing debt. The NBC Credit Agreement provides the Corporation with a \$4.0 million Revolving Credit Facility (“**2025 Revolving Facility**”) to finance working capital, capital expenditures and general corporate purposes, a \$3.0 million Delayed Draw Term Loan Facility (“**Acquisition Line**”) to finance future permitted acquisitions and a 10-year Term Loan Facility (“**2025 Term Loan**”) and collectively, with the 2025 Revolving Facility and the Acquisition Line, the “**NBC Credit Facilities**”) of \$6.5 million to consolidate and refinance existing bank debt, the Debentures and related party loans. The NBC Credit Facilities replaced the RBC Credit Facility. For further information, see “*Description of the Business - Credit Facility*”.

On March 6, 2025, the Corporation announced it had performed the first-ever injection of Arthroamid<sup>®</sup> in North America at its Mississauga, Ontario clinic. Arthroamid (2.5% iPAAG) is a unique non-biodegradable hydrogel injection developed by Contura International A/S, a biotechnology company based in Denmark. Unlike traditional osteoarthritis injections, Arthroamid integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single dose. It has been shown to provide up to four years of pain relief for knee osteoarthritis sufferers<sup>(1)</sup>. Arthroamid is currently available at select NeuPath clinics and will be rolled out at additional clinics across Canada in 2025.

On February 21, 2025, the Corporation received updated Notices of Reassessment from the Canadian Revenue Agency (“**CRA**”) in response to a Notice of Objection the Corporation filed with the CRA in August 2023. The matter pertained to the CRA HST audit decision with claims amounting to approximately \$0.2 million for the 2015 and 2016 filing periods. In December 2024, the Corporation received a positive response from the CRA confirming the objection was allowed. During March 2025, the Corporation received a total refund amount of approximately \$0.2 million, including interest.

### Fiscal 2024 (January 1, 2024 – December 31, 2024)

On November 27, 2024, the Corporation announced the approval by the TSXV of its launch of a normal course issuer bid (the “**NCIB**”) to purchase for cancellation up to 2,820,044 Common Shares (representing approximately 5% of the total number of its Common Shares outstanding as at November 27, 2024) over a twelve-month period commencing on November 27, 2024 and ending no later than November 26, 2025 (or on such date that the Corporation completes its purchases or provides notice of termination). For further information, see “*Description of Capital Structure - Description of Normal Course Issuer Bid*”.

On January 12, 2024, the Corporation completed the acquisition of the assets of SIBI Medical Inc., operating as the London Spine Centre in London, Ontario. The London Spine Centre has an interdisciplinary group of healthcare providers that use evidence-based care to help treat back, neck and other spinal conditions. These physicians have extensive experience in treating and diagnosing spinal conditions, and their affiliate therapists focus on treating the physical and mental aspects of acute and chronic pain using best practices, with an emphasis on functional recovery and return to work. This acquisition is in furtherance of the Corporation’s continued effort to expand its presence and its roster of specialists in the region.

---

<sup>1</sup> Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024, Aalborg and Orthopaedic Proceedings of the Bone & Joint Journal.

### **Fiscal 2023 (January 1, 2023 - December 31, 2023)**

On November 13, 2023, the Corporation announced the closing of a new credit facility (the “**RBC Credit Facility**”) with its existing lender Royal Bank of Canada (“**RBC**”). The RBC Credit Facility provided the Corporation with up to \$5.0 million of borrowings structured as a \$3.5 million revolving operating line, a \$0.5 million lease facility and refinancing of existing term debt up to \$1.0 million. On March 26, 2025, the Corporation replaced the RBC Credit Facility with the NBC Credit Facilities and all amounts outstanding under the RBC Credit Facility were repaid and the RBC Credit Facility was subsequently closed. For further information, see “*Description of the Business - Credit Facility*”.

On August 31, 2023, the Corporation completed the sale of its corporate-owned medical facility in London, Ontario for gross proceeds of \$2.1 million, and used a portion of the net proceeds from the sale to fully discharge the \$1.2 million mortgage secured by this facility. The gain on sale of the facility amounted to \$0.8 million after accounting for a net book value of \$1.2 million and related closing costs.

On May 15, 2023, the Corporation announced it had received notice that the CRA had allowed a number of the Corporation’s objections relating to its ongoing HST matter, and the CRA issued Notices of Reassessment. As a result, the CRA refunded \$1.9 million that was previously paid by and withheld from the Corporation.

On May 2, 2023, the Corporation announced the closing of its brokered private placement offering of 10% subordinated and postponed unsecured non-convertible debenture units of the Corporation (the “**Units**”) for gross proceeds of \$1.5 million (the “**Offering**”). On March 26, 2025, the Corporation provided notice to holders of its Debentures of its intention to redeem all outstanding Debentures, being the aggregate amount of \$1,453,000 of Debentures as of April 25, 2025 (the “**Redemption Date**”). As a result of the early redemption, the Corporation paid an amount equal to \$1,030 for each \$1000 principal amount of Debentures outstanding, being equal to the aggregate amount of \$1,496,590, plus all accrued and unpaid interest up to, but excluding, the Redemption Date (the “**Total Redemption Price**”). Proceeds from the 2025 Term Loan that are being used to pay the Total Redemption Price are being held in trust by TSX Trust Company, as debenture trustee, until the Redemption Date. Upon payment of the Total Redemption Price on the Redemption Date, all Debentures redeemed shall be cancelled and the previous holders of Debentures shall have no rights in respect thereof, except to obtain payment of their portion of the Total Redemption Price. For further information, see “*Description of Capital Structure - Description of Subordinated and Postponed Unsecured Non-convertible Debentures*”.

On March 9, 2023, Joseph Walewicz was appointed Chief Executive Officer of the Corporation. Mr. Walewicz was Interim Chief Executive Officer since September 30, 2022.

### **Fiscal 2022 (January 1, 2022 - December 31, 2022)**

In November 2022, the Corporation opened a new fluoroscopy suite in Ottawa. The Corporation has six fluoroscopy suites including two in Ontario and four in Alberta. The fluoroscopy suites expand the Corporation’s service offering to include image guided procedures.

On October 19, 2022, the Corporation announced Daniel Chicoine accepted the role of Chair of the Corporation’s Board, replacing Dianne Carmichael who stepped away for health reasons on September 30, 2022. In addition, Grishanth Ram also resigned from the Board on October 19, 2022 to pursue other endeavours.

In July 2022, the Corporation opened two new fluoroscopy suites in Red Deer, Alberta enabling the Corporation to better serve its patients and expand the service offerings.

On July 25, 2022, the Corporation announced its strategic growth plan to significantly accelerate the growth of its care for patients across Canada who suffer from pain and pain-related musculoskeletal conditions. The Corporation announced that it intended to expand its geographic reach and tools available to its teams in order to further deliver the most comprehensive and coordinated treatment solutions for its patients.

On March 17, 2022, Jeff Zygouras was appointed Chief Financial Officer and Corporate Secretary of the Corporation, who has been with the Corporation since 2019 and had previously served the Corporation as Interim Chief Financial Officer and Corporate Controller of the Corporation.

On February 2, 2022, the Corporation announced that it had received the approval from the TSXV to extend the exercise period of its outstanding Prefunded Warrants for an additional year from February 23, 2022 to February 23, 2023. All other terms of the Prefunded Warrants remained unchanged. On July 4, 2022, 2,890,000 Prefunded Warrants with an exercise price of \$0.0001 were exercised for Common Shares. On February 18 and 19, 2023, the remaining 4,305,000 Prefunded Warrants were exercised at an exercise price of \$0.0001. The Prefunded Warrants were originally issued on February 23, 2018 as part of a debt settlement agreement between 257 and the remaining holders of convertible debt of Viable Healthworks in settlement of approximately \$7,815,000 in outstanding debt. Further information on the debt settlement can be found in the Corporation's Annual Information Form for the year ended December 31, 2020 dated March 25, 2021, filed on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

## DESCRIPTION OF THE BUSINESS

### Overview

NeuPath's mission is to improve access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centred multidisciplinary care, enabling each individual to live their best life.

The Corporation's vision is to build the leading national network of clinics, recognized for their best-in-class quality of care, empathy-driven efficient service and leading-edge techniques to treat patients with chronic medical conditions.

The Corporation operates a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. NeuPath's healthcare providers cover a broad range of specialties and include: Psychiatrists, Neurologists, Anesthesiologists, Orthopedic Surgeons, General Practitioners with specialized training in chronic pain, as well as Medication Management Physicians, Athletic Therapists, Psychotherapists, Dietitians, Nurses and other allied health practitioners.

The Corporation also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices, through a national network of healthcare providers, including: Cardiologists, Dentists, Dermatologists, Endocrinologists, Psychiatrists, Gastroenterologists, General Practitioners, Internal Medicine Specialists, Neurologists, Neuropsychiatrists, Neuropsychologists, Occupational Therapists, Ophthalmologists, Orthopedic Surgeons, Psychiatrists, Physiotherapists, Psychologists, Respiriologists and Rheumatologists.

The Corporation has 11 locations across Ontario and two locations in Alberta staffed with more than 154 healthcare providers. In addition, the Corporation has a minority equity ownership in two physiotherapy and sport medicine clinics in Alberta.

### Markets

The Corporation competes in the chronic pain, sports medicine, concussion and workplace health services markets in Canada. Conditions often coexist amongst these distinct markets, for example, chronic pain is one of the known consequences of a traumatic brain injury. NeuPath believes that having the ability to treat these often-coexisting conditions and building collaborative, interdisciplinary teams of healthcare providers are distinct competitive advantages and are important foundations for improving patient care.

### Chronic Pain

Chronic pain impacts approximately 1 in 5 adults worldwide<sup>2</sup>. Despite chronic pain's prevalence and impact, it has only recently started to attract increased attention. In May 2019, the World Health Organization, for the first time, added chronic pain to its International Classification of Diseases. The International Classification of Diseases is used worldwide as a diagnostic tool to classify causes of injury or death and the addition of chronic pain will allow for

---

<sup>2</sup> BU School of Public Health. (2017). Chronic Pain and the Health of Populations. Retrieved from <https://www.bu.edu/sph/news/articles/2017/chronic-pain-and-the-health-of-populations/>.

better tracking of the impact and prevalence of chronic pain. In March 2019, Health Canada formed the Canadian Pain Task Force (“**Task Force**”) to provide advice regarding evidence and best practices for the prevention and management of chronic pain. The Task Force concluded its mandate at the end of 2021 and during the three-year period presented their findings to Health Canada. Subsequently, Health Canada established a dedicated team to pursue engagement with pain stakeholders and coordinate the federal response to the Task Force recommendations<sup>3</sup>.

A study found that chronic pain costs between \$38-\$40 billion in Canada in 2019, of which \$15-\$17 billion represents direct healthcare costs<sup>4</sup>.

## **Products and Services**

### Clinical Services

For the fiscal year ended December 31, 2024, clinical services accounted for 92% (92% in 2023) of the Corporation’s revenue.

#### 1. Chronic Pain Management Services – The Corporation’s Multimodal Approach

Chronic pain is a multidimensional condition impacted by biological, behavioural and social factors<sup>5</sup>. The Corporation’s health providers consider each of these factors when assessing and treating each patient. Traditional medical treatments may be supplemented as appropriate with access to medical cannabis, the Corporation’s Chronic Pain Self-Management Program and mindfulness meditation. This multimodal approach goes beyond treating the pain sensation and targets some of the underlying and contributing behavioural and social factors. In addition, the multimodal approach provides patients with the education and tools needed to help self-manage their chronic condition.

The Corporation generates revenue by providing both insured and uninsured services to patients. Insured services include treatments or procedures covered by provincial health plans and third-party health insurance plans. In most cases, the insurer is billed directly by the Corporation. Uninsured services include treatments and procedures that are not covered by provincial health plans or third-party health insurance plans and are billed directly to patients. For example, therapeutic botox injections are not covered by provincial health plans and, depending on a patient’s third-party health insurance coverage, may not be covered by third-party insurance. In this instance, the patient would need to pay out-of-pocket for the treatment.

Generally, patients are referred to the Corporation’s clinics by family physicians, specialists, dentists, nurse practitioners or other allied health professionals after experiencing pain for at least three months. Prior to their first visit, patients complete an extensive questionnaire. The questionnaire is designed to gain a better understanding of the patient’s pain, the impact of such pain on their life, and the patient’s medical history and lifestyle. Patients then complete an assessment with one of the Corporation’s chronic pain practitioners. The goal of the assessment is to gain a better understanding of the patient’s condition in order to create a treatment plan. Every patient is different from a biological, behavioural, and social perspective, so treatment plans reflect these differences and vary from patient to patient. Common elements of treatment plans include:

- (a) Injection-based and Interventional Therapies: The Corporation’s physicians inject analgesics around a specific nerve or bundle of nerves with the goal of reducing pain intensity. These analgesic injections are covered to varying degrees by provincial health plans. Nerve fibres may also be targeted by the insertion of specialized radiofrequency ablation needles which use thermal energy to disable nerve fibres and reduce or

---

<sup>3</sup> Government of Canada. Retrieved from: <https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force.html>.

<sup>4</sup> The Canadian Pain Task Force. (2020). Working Together to Better Understand, Prevent, and Manage Chronic Pain: What We Heard. Cat.: H134-17/2020E-PDF. Retrieved from <https://www.canada.ca/content/dam/hc-sc/documents/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2020-rapport/report-2020.pdf>.

<sup>5</sup> Lynch ME. The need for a Canadian pain strategy. *Pain Res Manag.* 2011 Mar-Apr; 16(2): 77–80; and Gatchel, Robert & Peng, Yuan & Peters, Madelon & Fuchs, Perry & Turk, Dennis. (2007). The Biopsychosocial Approach to Chronic Pain: Scientific Advances and Future Directions. *Psychological bulletin.* 133. 581-624. 10.1037/0033-2909.133.4.581.

eliminate pain intensity. In addition, the Corporation also offers therapeutic Botox injections for the treatment and prevention of chronic migraines. Botox injections are covered by some third-party health insurance plans.

- (b) Infusion Therapies: At select clinic locations, the Corporation offers intravenous lidocaine and ketamine infusion therapies for the treatment of neuropathic pain, complex regional pain syndrome, and chronic diabetic neuropathy. In general, provincial health insurance plans offer coverage for certain intravenous infusion therapies.
- (c) Chronic Pain Programs: NeuPath offers various programs to assist patients who are struggling with chronic pain. This includes a self-management program based on research conducted at Stanford University, called Empowered Relief, as well as our psychiatrist-driven multi-clinic program in Alberta. These programs employ a psychoeducational and cognitive behavioral approach which helps patients better understand chronic pain and teaches non-medicated coping strategies and goal setting. Similar programs have shown significant short-term improvements in pain, dependency, vitality, aspects of role functioning, life satisfaction and self-efficacy<sup>6</sup>.
- (d) Optimization of Pharmacotherapy: The Canadian Pain Society's guidelines for the treatment of neuropathic pain recommend gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors as first-line agents for treating neuropathic pain. Tramadol and other opioids are also recommended as second-line agents for treating neuropathic pain and some physicians may also prescribe medical cannabis through licensed providers. Often, the treatments patients receive at the Corporation's clinics will allow the Corporation's physicians to optimize, reduce, eliminate, or replace patients' other pain medications.

## 2. Workplace Health Services

The Corporation also provides workplace health services and independent medical assessments to law firms, employers and disability insurers through a national network of health care providers.

Spending on employee benefit group life and health plans in Canada was estimated to be \$59.7 billion in 2023, with \$28.6 billion spent on medical benefits<sup>7</sup>. A significant portion of this cost is allocated to traditional benefits such as medical, dental, and life/AD&D. According to a report by the Conference Board of Canada, healthcare costs in Canada are expected to increase substantially over the next decade due to an aging population and population growth<sup>8</sup>. Without substantial increases in public funding, Canadians could experience a reduction in access to care and employers could see a corresponding increase in lost productivity.

A study completed by Deloitte in 2019 found that employers are increasingly aware that conditions like mental illness are costly for employers<sup>9</sup>. As a result, some employers are investing in workplace mental health initiatives and, more importantly, are generating a positive return on investment. Based on early experiences with workplace mental health initiatives, employers may look to implement other workplace health initiatives to address conditions like pain that impact absenteeism, presenteeism and reduce short- and/or long-term disability.

### Non-Clinical Services

For the fiscal year ended December 31, 2024, non-clinical services accounted for 8% (8% in 2023) of the Corporation's revenue.

---

<sup>6</sup> LeFort, S., Gray-Donald, K., Rowat, K.M. & Jeans, M.E. Randomized controlled trial of a community-based psychoeducation program for the self-management of chronic pain. *Pain*, 74, 297-306, 1998.

<sup>7</sup> Fraser Group. (2023). Group Universe Report. Retrieved from <https://frasergroup.com/wp-content/uploads/2024/07/GUR-Public-Release-Canada-2023.pdf>.

<sup>8</sup> The Conference Board of Canada. (2020). Health Care Cost Drivers in Canada: Pre-and Post-COVID-19. Publication: 10816. Retrieved from [https://www.canadaspremiers.ca/wp-content/uploads/2020/10/CBOC\\_impact-paper\\_research-on-healthcare\\_final.pdf](https://www.canadaspremiers.ca/wp-content/uploads/2020/10/CBOC_impact-paper_research-on-healthcare_final.pdf).

<sup>9</sup> Deloitte. (2019). The ROI in workplace mental health programs: Good for people, good for business. Retrieved from <https://www2.deloitte.com/content/dam/Deloitte/ca/Documents/about-deloitte/ca-en-about-blueprint-for-workplace-mental-health-final-aoda.pdf>.

## 1. Physician Staffing Services

The Corporation provides physician staffing for provincial and federal correctional institutions across Canada. The Corporation receives compensation for physician staffing services on a quote pay per use and quote basis, which is calculated at an hourly rate.

## 2. Research

Through a wholly owned subsidiary, NeuPath provides contract research services to pharmaceutical companies. More importantly, these clinical research capabilities allow the Corporation to evaluate the efficacy of new and existing services and treatments. On April 11, 2023, the findings of a 562-patient study focused on chronic pain and the impact of NeuPath's treatments on patients' lives was published in the online journal *Cureus*<sup>10</sup>. The study participants, who previously reported low levels of functioning across several daily life activities, experienced significant improvements in all measured daily life activities after undergoing NeuPath's interdisciplinary treatment. The results of this study present an exciting opportunity for NeuPath to improve the quality of life for patients by applying cutting-edge and research-driven best practices.

### **Business and Growth Strategy**

#### Regional Approach to Pain Management Clinics

The Corporation seeks to develop leading positions in key markets and to leverage operational efficiencies by combining smaller local pain management clinics within a region under a single regional management structure. The Corporation's scale and density within selected geographic areas provides valuable and mutually beneficial long-term relationships with the local physicians, local nurse practitioners and the community in general.

#### Patient Centred Treatment Model

The Corporation provides patients with assessments and treatment plans based on the biopsychosocial approach. Research demonstrates the efficacy of the biopsychosocial approach in assessing and treating chronic pain. NeuPath believes this multimodal approach offers patients a superior alternative to the traditional monomodal treatments and long wait times at multidisciplinary pain clinics.

#### Growth Strategy

The Corporation's growth strategy is focused on three key pillars:

*Increased capacity utilization* - The Corporation's focus is to generate revenue growth by improving capacity utilization at its existing medical clinics. To achieve this objective, the Corporation intends to continue adding complementary services and healthcare provider hours, with a focus on improving patient throughput. For the year ended December 31, 2024, capacity utilization was 75% compared to 68% in the comparative year.

*Expanding the network* - The Corporation intends to build out a pan-Canadian network through acquisitions and new clinic startups. The market for medical clinics is highly fragmented in Canada. In February 2021, the Corporation acquired HealthPointe in Edmonton as the first step in its expansion into Western Canada. In July 2022, in partnership with Central Alberta Orthopedics Inc., the Corporation opened a new clinic, through HealthPointe@CAO, which provides interdisciplinary pain management services for patients in Red Deer, Alberta. In January 2024, the Corporation acquired the assets of SIBI Medical Inc., operating as the London Spine Centre in London, Ontario in furtherance of its continued effort to expand its presence and its roster of specialists in the region.

*Expanding into adjacent markets* - Orthopedics and other specialties have patients with high overlap to the Corporation's core chronic pain business, and the Corporation is actively evaluating new opportunities in these areas.

---

<sup>10</sup> Jovey R D, Balon J, Mabee J, et al. (April 11, 2023) Patients Response to Interventional Care for Chronic Pain Study (PRICS): A Cross-Sectional Survey of Community-Based Pain Clinics in Ontario, Canada. *Cureus* 15(4): e37440. doi:10.7759/cureus.37440.

The Corporation's facilities may also be utilized, with modest investment, to provide other services such as out-of-hospital surgery.

While executing on the growth strategy, NeuPath is focused on improved operating margins and has made changes to its corporate functions and its clinic footprint and will continue to evaluate opportunities for improving margins across the network.

## **Credit Facilities**

### *RBC Credit Facility*

On November 13, 2023, the Corporation announced the closing of the RBC Credit Facility. On March 26, 2025, the Corporation announced the replacement of the RBC Credit Facility with the NBC Credit Facilities. All amounts outstanding under the RBC Credit Facility were repaid with proceeds received from the Term Loan and the RBC Credit Facility was subsequently terminated including the discharge of all security previously provided to RBC.

### *NBC Credit Facilities*

On March 26, 2025, the Corporation entered into the NBC Credit Agreement with National Bank, which provides the Corporation with access to aggregate amount of \$13.5 million in cash, comprised of: (i) 2025 Revolving Facility; the (ii) Acquisition Line and (iii) the 2025 Term Loan.

The 2025 Revolving Facility permits the Corporation to draw amounts at any time, subject to satisfying certain financial covenants, including without limitation, the requirement to meet a total debt to Adjusted EBITDA ratio of less than or equal to 3:75:1, for working capital, capital expenditures and general corporate purposes.

The Acquisition Line is made available to the Corporation by way of a maximum of three advances, with each advance being for no less than \$1.0 million to finance future acquisitions, subject to certain terms and conditions.

The 2025 Term Loan is made available to the Corporation by way of a single advance in the amount of approximately \$6.5 million for the purpose of consolidating and refinancing the Corporation's existing debt. As a result of the 2025 Term Loan, the Corporation has repaid all amounts outstanding under the RBC Credit Facility. In addition, the Corporation has redeemed all outstanding Debentures and repaid all outstanding related party loans. For further information see "*Description of Capital Structure – Description of Subordinated and Postponed Unsecured Non-convertible Debentures*".

Interest rates for amounts outstanding under the Credit Facilities are calculated based on the National Bank's prime lending rate, plus applicable margins, which are calculated based on certain financial ratios. As of the date of this AIF, the Corporation has not drawn down on the Revolving Facility or the Acquisition Line and has \$6.5 million outstanding on the Term Loan.

Pursuant to the terms and conditions of the NBC Credit Agreement, the NBC Credit Facilities will be secured by substantially all of the assets of the Corporation and its subsidiaries. Additionally, the Corporation will be required to meet certain financial covenants and to satisfy various affirmative and negative covenants that limit, among other things, the Corporation's ability to incur additional indebtedness outside of permitted indebtedness. The NBC Credit Agreement also includes customary events of default, including payment and covenant breaches, bankruptcy events and the occurrence of change of control.

## **Locations**

The Corporation currently operates 12 chronic pain management clinics across Alberta and Ontario, all of which operate in leased office space. In addition, the Corporation has a minority equity ownership in two physiotherapy and sport medicine clinics in Alberta.

During the fiscal year ended December 31, 2024, the Corporation moved its Mississauga and Hamilton clinics to new leased office spaces as a result of the expiry of existing lease agreements. In addition, the Corporation leased a new corporate head-office space in Mississauga.

The Corporation's leased properties are all leased from third parties on terms and conditions that are customary in commercial leases of this nature. Each of the Corporation's leased properties are listed below:

<b>Leased Properties</b>	<b>Lease Expiration Date</b>
Windsor	March 31, 2025
Brampton	July 31, 2025
Oshawa	November 30, 2025
Hamilton	November 30, 2025
Kitchener	December 31, 2025
Mississauga	January 31, 2026
Tofield	May 31, 2026
Ottawa	July 31, 2028
Hamilton	November 29, 2029
London	June 30, 2030
Scarborough	July 31, 2030
Red Deer	July 31, 2032
Edmonton	December 31, 2033
Mississauga	February 28, 2034

### **Competitive Conditions**

The primary healthcare market is a very fragmented environment with thousands of medical clinics spread across Canada and the majority of these clinics are owned and managed by physicians. A lack of professional management and other associated infrastructure limits their ability to grow beyond a single location or small, regional network of clinics. In Ontario, there are more than 60 chronic pain management clinics alone, many of which are single-location clinics without broad programs or scaling efficiencies. With 13 clinics across Canada, the Corporation is the largest provider of chronic pain management services in Canada.

### **Employees**

As at December 31, 2024, the Corporation had 148 employees. In addition, the Corporation uses the services of professional consultants, such as physician consultants from time to time. As of December 31, 2024, approximately 63 employees are represented by a union covered by a collective bargaining agreement entered into in June 2021 and remains in effect until March 2025. The Corporation is currently negotiating a new collective bargaining agreement with the union and anticipates a new collective bargaining agreement to be entered into in April 2025. The Corporation has not experienced nor does the Corporation anticipate any labour-related work stoppages at its Ontario clinics during the negotiation phase.



## **RISK FACTORS**

*The Corporation considers the risks set out below to be the most significant to potential investors in the Corporation, but this list does not contain all of the risks associated with an investment in the securities of the Corporation. If any of these risks materialize into actual events or circumstances or other possible additional risks and uncertainties of which the Corporation is currently unaware or which it considers not to be currently material in relation to the Corporation's business actually occur, the Corporation's assets, liabilities, financial condition, results of operations (including future results of operations), business and business prospects are likely to be materially and adversely affected. In such circumstances, the price of the Common Shares may decline and investors may lose all or part of their investment. Investors should carefully consider the risk factors set out below and all other information contained in this AIF and in the Corporation's other public filings before making an investment decision. An investment in the Common Shares is speculative and involves a high degree of risk due to the nature of the Corporation's business. It is recommended that investors consult with their own professional advisors before investing in the Common Shares.*

### **Risk Factors relating to the Corporation's Business and Industry**

#### ***Governmental regulation and funding, permits and licenses***

Government regulations and funding play a key role in the Canadian healthcare sector. Any alleged failure by the Corporation to comply with applicable laws and regulations may lead to the imposition of fines and penalties or the denial, revocation or delay in the renewal of permits and licenses issued by governmental authorities. Furthermore, government policy related to healthcare spending can change and decisions can be made regarding funding that are largely beyond the Corporation's control. For example, if government funding for healthcare becomes limited, the Corporation's future customers may be unable to pay their obligations on a timely basis or to make payment in full and it may become necessary to increase reserves. Any change in governmental regulation, delisting of services, and licensing requirements relating to healthcare services could adversely affect the Corporation's financial condition and results of operations. In addition, complying with changes in government regulations could require significant investments or could result in increased costs for the Corporation. The Corporation may also be subject to audits, fines, or other penalties in the event of non-compliance with regulations, either existing or proposed. Non-compliance could also adversely affect the reputation, operations or financial performance of the Corporation.

#### ***Geographic concentration***

All of the Corporation's clinics are located in Canada, specifically in the Province of Ontario and the Province of Alberta. As a result, the Corporation's performance will be particularly sensitive to economic, political and regulatory changes in Canada, generally, and in the Province of Ontario and the Province of Alberta, specifically. Adverse changes in the economic condition, political or regulatory environment in Canada, generally, and in the Province of Ontario and the Province of Alberta, specifically may have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows.

#### ***Reliance on healthcare professionals***

Physicians and other healthcare professionals provide essential services to the Corporation. An interruption, either temporary or permanent, in services provided by physicians and other healthcare professionals to the Corporation or its patients could have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows. In addition, the Corporation's growth initiatives heavily rely on securing the services of additional physicians and other healthcare professionals. There are periodic shortages of certain medical physicians in Canada and this may affect the Corporation's ability to secure the services of additional physicians and other healthcare practitioners in order to successfully execute the Corporation's growth initiatives.

As of December 31, 2024, approximately 63 employees are represented by a union covered by a collective bargaining agreement. While the Corporation maintains a positive relationship with its respective union, future renegotiations of the collective bargaining agreement could result in work disruption including work stoppages or work slowdowns. Should a work stoppage occur, it could interrupt the Corporation's operations at the impacted clinics, which in turn could have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows.

### ***Future acquisitions***

While the Corporation is focused on growing its business organically, acquisitions and other strategic transactions remain an important part of the Corporation's growth strategy. The Corporation may acquire assets or businesses that it believes will provide more tools or allow the Corporation to provide more patients with the care and tools they need to live a complete and fulfilled life. In the future, the Corporation may not be able to successfully identify attractive acquisitions or other strategic transaction opportunities or make acquisitions or other strategic transactions on terms that are satisfactory to the Corporation from a commercial perspective. In addition, competition for acquisitions in the industries in which the Corporation operates may increase the price of acquisitions or other strategic transactions, which could cause the Corporation to refrain from making certain acquisitions. The Corporation's ability to execute on opportunities may also be affected by factors beyond its control, including without limitation, commercial or regulatory changes. On January 12, 2024, the Corporation completed the acquisition of the assets of SIBI Medical Inc., operating as the London Spine Centre in London, Ontario. See "*General Development of Business – Fiscal 2024 (January 1, 2024 – December 31, 2024)*" for further information. The Corporation's acquisition strategy involves numerous risks, including, without limitation:

- i. certain of the Corporation's acquisitions may prove unprofitable and fail to generate anticipated cash flows;
- ii. to successfully manage a growing portfolio of medical services businesses and other properties, the Corporation may need to recruit additional senior management as there can be no assurance that senior management of acquired companies will continue to work for the Corporation and, in a highly competitive labour market, the Corporation cannot be certain that any of its recruiting efforts will succeed. In addition, the Corporation may need to expand corporate infrastructure to facilitate the integration of its operations with those of acquired properties, because failure to do so may cause the Corporation to lose the benefits of any expansion that it decides to undertake by leading to disruptions in the Corporation's ongoing businesses or by distracting management;
- iii. entry into markets and geographic areas where the Corporation has limited or no experience;
- iv. the Corporation may encounter difficulties in the integration of operations and systems, app technology or other software infrastructure;
- v. management's attention may be diverted from other business concerns; and
- vi. the Corporation may lose key employees of acquired companies.

### ***Growth initiatives***

The Corporation's ability to successfully grow its business through increasing utilization rates at existing clinics and through acquisitions will be dependent on a number of factors, including: successfully recruiting and training additional healthcare providers, attracting sufficient referrals from new and existing healthcare providers, the identification of suitable acquisition targets in both new and existing markets, the negotiation of purchase agreements on satisfactory terms and prices, securing attractive financing arrangements, and the integration of newly acquired operations into the existing business. Any acquisition will involve a number of risks, including: the inability to integrate the operations, personnel and information systems of the acquired business, the potential acquisition of previously undisclosed liabilities, the possibility that the Corporation pays more than the acquired business is worth, the increase in the operating complexity of the Corporation as a result of the acquisition, and the potential disruption of the Corporation's ongoing business and the diversion of management's attention from its day-to-day operations. Any failure by the Corporation to manage its acquisition strategy successfully could have a material adverse effect on the Corporation's business, results of operations and financial condition.

### ***Reliance on third-party referrals***

The success of the Corporation's business depends, in part, in its ability to attract new patients, particularly in markets in which the Corporation has limited clinics or no brand awareness. In order to expand its patient base in these markets as well as existing markets, the Corporation depends on patient referrals from unaffiliated physicians, nurse practitioners and other third parties who have no contractual obligations to refer patients to the Corporation's clinics. If a significant number of physicians and other third parties were to discontinue or significantly reduce the rate at which they refer patients to the Corporation's clinics, the Corporation's treatment volume could materially decrease, which would reduce its revenue and operating margins, which could have a material adverse effect on the Corporation's business and financial condition.

## ***Cybersecurity and information technology***

The Corporation relies on information technology systems to process, transmit and store sensitive and confidential data, including protected health information, personally identifiable information, and proprietary and confidential business performance data. As a result, the Corporation and/or its customers are exposed to risks related to cybersecurity. Such risks may include unauthorized access, use, or disclosure of sensitive information (including confidential patient health records), corruption or destruction of data, or operational disruption resulting from system impairment (e.g., malware). Cyber-threats and cyber-attacks vary in technique and sources, are persistent, frequently change and are increasingly becoming more sophisticated, targeted and difficult to detect and prevent. Third parties to whom the Corporation outsources certain functions, or with whom their systems interface, are also subject to the risks outlined above and may not have or use appropriate controls to protect confidential information. A breach or attack affecting a third-party service provider or partner could harm the Corporation's business even if the Corporation does not control the service that is attacked.

The Corporation employs a multi-layered cybersecurity approach to safeguard sensitive data and critical systems. Technology Systems such as Managed Detection and Response for continuous threat monitoring and rapid incident response, Advanced Threat Protection to detect and mitigate sophisticated cyber threats, and Security Awareness Training to educate employees on best practices and emerging risks. These proactive measures strengthen our security posture, minimize vulnerabilities, and ensure compliance with industry standards.

The Corporation's operations depend, in part, on how well it protects networks, equipment, information technology systems and software against damage from a number of threats, including, but not limited to, damage to hardware, computer viruses, hacking and theft. The Corporation's operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, information technology systems and software, as well as pre-emptive expenses to mitigate the risks of failures. A compromise of the Corporation's information technology systems or confidential information, or that of the Corporation's patients and third parties with whom the Corporation interacts, may result in negative consequences, including the inability to process patient transactions, reputational harm affecting patient and/or investor confidence, potential liability under privacy, security, consumer protection or other applicable laws, regulatory penalties and additional regulatory scrutiny, any of which could have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows for which the Corporation's insurance policies may not provide adequate compensation.

In addition, the jurisdictions in which the Corporation operates have adopted breach of privacy and data security laws or regulations that require notification to consumers if the security of their personal information is breached, among other requirements. A Parliamentary Committee has recently recommended certain changes to *Personal Information Protection and Electronic Documents Act* (Canada), the federal privacy and data protection statute in Canada, including new administrative enforcement powers and new financial penalties for non-compliance. There is a risk that the government may implement changes to this statute that may result in additional compliance or changes in our business practices, or create additional risk of liability or sanction, or all of the foregoing. In addition, governmental focus on data security may lead to additional legislative action, and the increased emphasis on information security may lead patients to request that the Corporation take additional measures to enhance security or restrict the manner in which the Corporation collects and uses patient information. As a result, the Corporation may have to modify its business systems and practices with the goal of further improving data security, which would result in increased expenditures and operating complexity.

The Corporation's ongoing risk and exposure to these matters is partially attributable to the evolving nature of these threats. As a result, cybersecurity and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage, malfunction, human error, technological error or unauthorized access is a priority. As cyber-threats continue to evolve, the Corporation may be required to expand additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

## ***Competition***

The Corporation operates in competitive markets that can change rapidly and are highly impacted by the actions of other market participants. Aside from government regulations, licensing requirements, and relationships the Corporation has built up with healthcare providers, insurance companies, employers, and patients, there is little to

prevent the entrance of new competitors providing similar services to those that are provided by the Corporation. There can be no assurance that the Corporation will be able to compete effectively for referrals from healthcare providers or insurance companies if better capitalized or more experienced competitors enter the Corporation's markets. In addition, new competitors could make it difficult for the Corporation to recruit new healthcare providers.

#### ***Reliance on key personnel***

The Corporation is highly dependent upon its executive officers and key personnel. The unexpected loss of the services of any of these individuals could have a detrimental effect on the Corporation. There is no guarantee that the Corporation will retain members of its management team, and if the Corporation were to lose a member of its management team unexpectedly, its business, prospects, financial condition and results of operations may be adversely affected.

#### ***Confidentiality of personal and health information***

Employees and consultants of the Corporation and its subsidiaries, in the course of their duties, will have access to personal health information and, specifically, medical histories of patients or claimants of clients of the Corporation. There can be no assurance that the Corporation's policies, procedures and systems will be adequate to address privacy legislation or the privacy concerns of existing and future patients or clients. The Corporation could be liable for damages, fines, penalties, or reputational damage in the event of a privacy breach or if a patient or client's privacy is violated.

#### ***Reliance on third parties***

Third parties, including electronic medical record and information technology vendors, are integral to the Corporation's operations. If, for any reason, the Corporation could no longer access the services provided by these third parties, the Corporation would need to obtain such services from other providers. This could have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows.

#### ***Uncertainty of liquidity and capital requirements***

The Corporation's future capital requirements will depend on many factors, including the rate of growth of its patient base, the costs of expanding into new markets and the growth of the chronic pain, sports medicine, concussion, and workplace health services markets. In order to meet such capital requirements, the Corporation may consider additional public or private financing (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs, which could entail dilution of the Common Shares. There can be no assurance that additional funding will be available when needed or, if available, that it will be available on favourable terms. If the Corporation fails to obtain adequate capital on a timely basis or if capital cannot be obtained at reasonable costs, the Corporation may have to curtail acquisition activities, reduce substantially or otherwise eliminate certain expenditures, including marketing of its services, or obtain funds through arrangements with corporate partners that may require the Corporation to relinquish rights to certain assets. There can be no assurance that the Corporation will be able to raise additional capital if its capital resources are exhausted.

#### ***The Corporation's financial results and results of operations have fluctuated in past and may continue to be volatile going forward***

The Corporation's financial results may fluctuate as a result of a number of factors that may be outside of its control, which may cause the market price of the Common Shares to fall. For these reasons, comparing operating results on a period-to-period basis may not be meaningful, and an investor should not rely on past results as an indication of future performance. Financial results may be negatively affected by any of the risk factors listed in this "Risk Factors" section.

***The Corporation is subject to risks associated with leasing space and equipment. Any failure to make lease payments when due, or the inability to extend, renew or continue to lease space and equipment in key locations, would likely harm the Corporation's business, profitability and results of operations***

The Corporation leases all of its clinic locations. In accordance with the Corporation's growth strategy, it also intends to expand into new geographic regions within Canada. Accordingly, the Corporation is subject to all of the risks associated with leasing, occupying and making tenant improvements to real property.

The success of any of the Corporation's clinics depends substantially upon its location. There can be no assurance that the Corporation's current locations will continue to be desirable in the future, or that the Corporation will be able to secure new desirable locations in the future on favourable terms or at all. Patient conversion and revenues may be adversely affected by, among other things, social and economic conditions in a particular area, competition from nearby pain management treatment facilities, out-of-pocket treatment costs, and changing lifestyle choices of patients in a particular market. If the Corporation cannot obtain desirable locations at reasonable costs, the Corporation's cost structure will increase and its revenues will be adversely affected.

Some of the lease agreements have additional renewal options. However, there can be no assurances that the Corporation will be able to extend, renew or continue to lease its existing clinic locations, or identify and secure alternative suitable locations.

The Corporation depends on cash flow from operations to pay its lease expenses and to fulfill other cash needs. If the Corporation's business does not generate sufficient cash flow from operating activities to fund these expenses and sufficient funds are not otherwise available, the Corporation may not be able to service its lease expenses, which could harm its business. If an existing or future location is not profitable, and the Corporation decides to close it, the Corporation may nonetheless be committed to perform its obligations under the applicable lease including, among other things, paying the base rent for the balance of the lease term. In addition, if the Corporation is not able to enter into new leases or renew existing leases on terms acceptable to it, this could have an adverse effect on the Corporation's business and financial condition.

***The regulatory framework in which the Corporation operates is constantly evolving***

Healthcare laws and regulations are constantly evolving and could change significantly in the future. The Corporation closely monitors these developments and will modify its operations from time to time as the regulatory environment requires. There can be no assurances, however, that the Corporation will always be able to adapt its operations to address new law or regulations or that new laws or regulations will not adversely affect the Corporation's business. In addition, although the Corporation believes that it is operating materially in compliance with applicable federal and provincial laws and regulations, neither the Corporation's current or anticipated business operations nor the operations of the Corporation's contracted physician practices have been the subject of judicial or regulatory interpretation. The Corporation cannot assure investors that a review of the Corporation's business by courts or regulatory authorities will not result in a determination that could materially adversely affect the Corporation's operations or that the healthcare regulatory environment will not change in a way that materially restricts the Corporation's operations. Furthermore, governments, government agencies and industry self-regulatory bodies in the Canada may, from time to time, adopt statutes, regulations and rulings that directly or indirectly affect the activities of the Corporation. These regulations could adversely impact the Corporation's ability to execute its business strategy and generate revenues as planned.

***Insurance***

All physicians working for the Corporation will be covered by their own malpractice insurance policies. In addition, the Corporation will maintain general liability, fire and flood insurance with policy specifications, limits and deductions for its clinics. There can be no assurance that the coverage will be sufficient or that, in the future, policies will be available at adequate levels of insurance or at acceptable costs. Moreover, there are certain types of risks, generally of a catastrophic nature, such as wars or natural disasters, which are either uninsurable or not insurable on an economically viable basis. Should an uninsured or underinsured loss occur, the assets of the Corporation may not be sufficient to satisfy these losses and this may have a material adverse effect on the Corporation's business, financial position, results of operations or cash flows.

### ***Reliance on reimbursements by third-party insurance providers***

The Corporation's revenue levels will be affected by the percentage of its patients with third-party insurance coverage. A patient's insurance coverage may change for a number of reasons, including changes in the patient's or a family member's employment status. If there is a significant change in the Corporation's payor mix, resulting in a reduction in the number of patients with third-party insurance coverage declining, the Corporation's revenues, earnings and cash flows could be substantially reduced.

### ***Social Media***

Increasingly, social media is used as a vehicle to carry out cyber phishing attacks. Information posted on social media sites, for business or personal purposes, may be used by attackers to gain entry into the Corporation's systems and obtain confidential information. The Corporation does not restrict access to social media but through our Cyber Security Awareness Program educates its employees on the potential risks to the business. Despite these efforts, there are significant risks that the Corporation may not be able to properly regulate social media use and preserve adequate records of business activities and client communications conducted through the use of social media platforms.

### ***Internal controls***

Effective internal controls are necessary for the Corporation to provide reliable financial reports and to help prevent fraud. Although the Corporation will undertake a number of procedures and will implement a number of safeguards, in each case, in order to help ensure the reliability of its financial reports, including those imposed on the Corporation under applicable securities laws, the Corporation cannot be certain that such measures will ensure that the Corporation will maintain adequate control over financial processes and reporting. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Corporation's results of operations or cause it to fail to meet its reporting obligations. If the Corporation or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in the Corporation's consolidated financial statements and materially adversely affect the trading price of the Common Shares.

### ***Billing and collection systems***

The Corporation's billing system is critical to the Corporation's billing operations. If there are defects in the billing system, the Corporation may experience difficulties in its ability to successfully bill and collect for services rendered, including a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in uncollectible accounts receivable and non-compliance with reimbursement regulations, any or all of which could have a material adverse effect on the Corporation's revenues, cash flows and operating results.

In addition, the Corporation accepts payments using a variety of methods, including credit cards and debit cards. For existing and future payment methods the Corporation offers its patients, the Corporation may become subject to additional regulations and compliance requirements, as well as fraudulent activities. For certain payment methods, including credit and debit cards, the Corporation pays interchange and other fees, which may increase over time, raising the Corporation's operating costs and lowering profitability. The Corporation relies on third party service providers for payment processing services, including the processing of credit and debit cards. The Corporation's business may be negatively affected if these third-party service providers become unwilling or unable to provide these services to the Corporation. The Corporation is also subject to payment card association operating rules, including data security and management rules, certification requirements and rules governing electronic funds transfers and if the Corporation fails to comply with these rules or requirements, or if the Corporation's data security systems are breached or compromised, the Corporation may be liable for card issuing banks' costs, subject to fines and higher transaction fees and/or lose its ability to accept credit and debit card payments from its patients and process electronic funds transfers or facilitate other types of payments, and the Corporation's business and operating results may be adversely affected.

### ***Restrictions imposed by the RBC Credit Facility***

The Credit Facility imposes certain significant operating and financial restrictions on the Corporation. The Credit Facility includes various restrictive covenants relating to future acquisitions, indebtedness, operations, investments,

capital expenditures and other standard operating business covenants, which significantly limit the ability of certain of the Corporation's material operating subsidiaries.

These restrictions could limit the Corporation's ability to capitalize on attractive growth opportunities for its business or otherwise engage in activities that may be in the Corporation's long-term best interests that are currently unforeseeable, particularly if the Corporation is unable to secure financing or make investments to take advantage of such opportunities.

The failure of the Corporation to comply with these covenants could result in an event of default that, if not cured or waived, could result in the acceleration of substantially all amounts outstanding under the Credit Facility. The Corporation may not have sufficient working capital to satisfy such debt obligations in the event of an acceleration of the Credit Facility, which accounts for a significant portion of the Corporation's outstanding indebtedness. The Credit Facility is secured by all of the assets of the Corporation.

#### ***Risks of pending or future legal proceedings***

From time to time, the Corporation is involved in litigation relating to, among other things, labour, health and safety matters, regulatory, tax and administrative proceedings, governmental investigations, arbitration and contractual claims and disputes. In particular, the Corporation can be subject to claims relating to actions of medical personnel performing services at the Corporation's clinics.

Litigation is inherently costly and unpredictable, making it difficult to accurately estimate the outcome, among other matters. Although the Corporation has established financial provisions and contingencies, which it believes are individually appropriate, there is a risk that on a cumulative basis, adverse decisions in such matters could materially affect the Corporation's financial condition or results of operations if such contingencies vary significantly from any amounts actually paid. In addition, if the Corporation were to receive an unfavourable decision through such proceedings, the Corporation may suffer reputational damage as a result, which could have an adverse effect on the Corporation's business and its ability to grow.

Any litigation could result in substantial costs and diversion of resources and could have a material adverse effect on the Corporation's business, financial conditions and results of operations.

#### ***The Corporation may be subject to additional taxes, which could affect the Corporation's operating results***

The Corporation and its subsidiaries file all required income tax returns and is of the view that it is in material compliance with all applicable tax laws. However, such tax returns are subject to reassessment by the applicable jurisdictional tax authorities and the Corporation has been subject to such reassessments from time to time. In the event of a reassessment of the Corporation's tax returns, such reassessment may have an impact on current and future taxes payable.

Legislative changes may also have an adverse impact on the Corporation's operations and performance. Changes in tax related laws and regulations, and interpretations thereof, can affect tax burdens by increasing tax rates and fees, creating new taxes, limiting tax deductions, and eliminating tax-based incentives. In addition, jurisdictional tax authorities or courts may interpret tax regulations differently than the Corporation does, which could result in tax litigation and additional costs and penalties. Such legislative changes may have an adverse impact on the Corporation's business, financial condition and results from operations.

#### ***Global, political and economic conditions and uncertainties may impact the Corporation's operations***

Uncertainty, downturns and changes that impact the Corporation's business can arise as a result of conditions in global financial markets, changes in macroeconomic factors, changes in laws and regulations, political conditions and election outcomes, political and social unrest, wars and conflicts, terrorist acts, cyber-attacks, economic and regulatory sanctions, natural disasters and public health crises (such as epidemics and pandemics) and other factors over which the Corporation has no control. The global economy continues to experience substantial disruption and uncertainty due to rising geopolitical tensions, including the Russian invasion of Ukraine and related government sanctions and the ongoing Israel-Hamas conflict, ongoing protectionism measures due to a decline in global alignment, aggressive monetary tightening, weaker global demand, evolving interest rate increases and inflationary backdrop, supply chain

disruptions, labour shortages and other events. These factors may create unprecedented economic conditions including the possibility of an economic recession, that may last substantially longer than expected and create stress on economic growth and market volatility. The Corporation is unable to predict the extent of impact or duration of any such economic conditions, or their ultimate impact on operations of the Corporation. Such events could have an adverse impact on the Corporation's business, financial condition and results from operations.

### ***Interest Rates***

The Corporation's consolidated debt may accrue interest at a floating rate, and therefore the Corporation may be exposed to interest rate cash flow risk on floating interest rate bank debt due to fluctuations in market interest rates.

### ***Default on obligations to pay material debt facilities***

The Corporation may incur additional indebtedness subject to certain limitations. If the Corporation is unable to generate sufficient cash flow or is otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on the Corporation's indebtedness, or if the Corporation otherwise fails to comply with the various covenants in the instruments governing its indebtedness, the Corporation could be in default under the terms of the agreements governing this indebtedness. In this event, the holders of such indebtedness could elect to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest; the lenders could elect to terminate their commitments, cease making further loans and institute foreclosure proceedings against the Corporation's assets and the Corporation could be forced into bankruptcy or liquidation. If the Corporation's operating performance declines, it may need to obtain waivers from the required lenders to avoid being in default. If the Corporation breaches these covenants and seeks a waiver from the required lenders, it may not be able to obtain it. If this occurs, the Corporation would be in default under its indebtedness, the lenders could exercise their rights, as described above, and the Corporation could be forced into bankruptcy or liquidation.

### ***Management assumptions and contingencies***

Actual results may differ materially from management estimates and assumptions. In preparing consolidated financial statements in conformity with International Financial Reporting Standards, estimates and assumptions are used by management in determining the reported amounts of assets and liabilities, revenues and expenses recognized during the periods presented and disclosures of contingent assets and liabilities known to exist as of the date of the financial statements. These estimates and assumptions must be made because certain information that is used in the preparation of such financial statements is dependent on future events, and cannot be calculated with a high degree of certainty from information available and the Corporation must exercise significant judgment in applying its accounting policies, estimates and assumptions about the future.

Estimates may be used in management's assessment of items such as fair values, income taxes, net operating earnings or loss, contingent liabilities and reported amount of assets. Actual results for all estimates could differ materially from the estimates and assumptions used by the Corporation, which may have a material adverse effect on the Corporation's business, financial condition, results from operations and business prospects.

In addition, the presentation of financial information in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board requires that management apply certain accounting policies and make certain estimates and assumptions that affect reported amounts in the Corporation's consolidated financial statements. The accounting policies may result in non-cash charges to net income and write-downs of net assets in the consolidated financial statements. Such non-cash charges and write-downs may be viewed unfavourably by the market and may result in an inability to borrow funds and/or may result in a decline in the Common Share price.

### ***Potential conflicts of interests***

Certain directors and officers of the Corporation will also serve as directors and/or officers of other companies or may have significant shareholdings in other companies including companies in the same sector. Consequently, there exists the possibility for such directors and officers to be in a position of conflict. Any decision made by any of such directors and officers will be made in accordance with their duties and obligations to deal fairly and in good faith with a view to the best interests of the Corporation and its shareholders. In addition, each of the directors is required to declare and



refrain from voting on any matter in which such directors may have a conflict of interest, in accordance with the procedures set forth in the OBCA and other applicable laws.

### ***Increased costs as a result of being a public corporation***

As a public issuer, the Corporation is subject to the reporting requirements and rules and regulations under the applicable Canadian securities laws and rules of any stock exchange on which the Corporation's securities may be listed from time to time. Additional or new regulatory requirements may be adopted in the future. The requirements of existing and potential future rules and regulations will increase the Corporation's legal, accounting and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on its personnel, systems and resources, which could adversely affect its business, financial condition, and results of operations.

### ***The Corporation is a holding company***

The Corporation is a holding company and virtually all of its assets consist of the equity it holds in its subsidiaries. As a result, investors are subject to the risks attributable to the Corporation's subsidiaries and any and all future affiliates. The Corporation does not have any significant assets and conducts substantially all of its business through its subsidiaries, which generate all or substantially all of the Corporation's revenues. The ability of the Corporation's subsidiaries to distribute funds to the Corporation will depend on their operating results, tax considerations and will be subject to applicable laws and regulations, which require that solvency and capital standards be maintained by these subsidiaries and contractual restrictions contained in the instruments governing their debt, existing or if incurred. In the event of a bankruptcy, liquidation or reorganization of one or more of the Corporation's subsidiaries or any other future subsidiary, holders of indebtedness and trade creditors will generally be entitled to payment of their claims from the assets of those subsidiaries before any assets are made available for distribution to the Corporation.

### **Risks Related to the Common Shares**

#### ***The Common Shares will be subject to various factors that may make the price of the Common Shares volatile***

The market price of the Common Shares could fluctuate significantly, in which case it may not be possible to re-sell the Common Shares at or above the price of the Common Shares today. The market price of the Common Shares may fluctuate based on a number of factors in addition to those set out elsewhere herein, including: (i) the Corporation's operating performance and the performance of the competitors and other similar companies; (ii) the public's reaction to the Corporation's news releases, other public announcements and the Corporation's filings with the various securities regulatory authorities; (iii) changes in earnings estimates or recommendations by research analysts who track the Common Shares or the securities of other companies in the industry that the Corporation operates; (iv) changes in the general economic conditions and the overall condition of the financial markets; (v) the arrival or departure of key personnel; and (vi) acquisition, strategic alliances or joint ventures involving the Corporation or its competitors.

In addition, the market price of the Common Shares will be affected by many variables not directly related to the Corporation's success and not within the Corporation's control, including developments that affect the healthcare industry as a whole, the breadth of the public market for the Common Shares, and the attractiveness of alternative investments. In addition, securities markets have experienced an extreme level of price and volume volatility, and the market price of securities of many companies has experienced wide fluctuations, which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. As a result of these and other factors, the price of the Common Shares may be volatile in the future and may decline below the price of the Common Shares today. Accordingly, investors may not be able to sell its Common Shares at or above the price of the Common Shares today.

#### ***Liquidity***

The price of the Common Shares may fluctuate in response to a number of events and factors, including, but not limited to: the Corporation's financial condition, financial performance and future prospects, public announcements and the Corporation's filings with the various securities regulatory authorities and changes in general market and economic conditions. There can be no assurance that an active and liquid market will be developed for the Common

Shares, and if developed, it may not be sustained, and an investor may find it difficult to resell any securities of the Corporation.

### ***Dilution***

The Corporation may require additional funds in respect of the further development of its business. If the Corporation raises funds by issuing additional equity securities, such financing will dilute the equity interest of its shareholders.

### ***Any future profits will likely be used for the continued growth of the business and products and will not be used to pay dividends on the issued and outstanding Common Shares***

The Corporation will not pay dividends on the issued and outstanding Common Shares in the foreseeable future. If the Corporation generates any future earnings such cash resources will be retained to finance further growth and current operations. The Board will determine if and when dividends should be declared and paid in the future based on the Corporation's financial position and other factors relevant at the particular time. Until the Corporation pays dividends, which it may never do, a shareholder will not be able to receive a return on his or her investment in the Common Shares unless such Common Shares are sold. In such event, a shareholder may only be able to sell his, her or its Common Shares at a price less than the price such shareholder originally paid for them, which could result in a significant loss of such shareholder's investment.

### ***Significant shareholders***

The shareholding levels of certain shareholders of the Corporation will give such shareholders significant influence on decisions to be made by shareholders, including the ability to influence the election of directors of the Corporation as well as the approval of future transactions requiring shareholder approval. There is a risk that the interests of the Corporation's significant shareholders will differ from those of other shareholders.

### ***Sale of the Corporation's securities by directors, officers and/or significant shareholders***

Subject to compliance with applicable securities laws, directors, officers and/or significant shareholders may sell some or all of their Common Shares in the future. No prediction can be made as to the effect, if any, such future sales of Common Shares by directors, officers and/or significant shareholders will have on the market price of the Common Shares prevailing from time to time. However, the future sale of a substantial number of Common Shares by management shareholders and/or significant shareholders, or the perception that such sales could occur, could adversely affect prevailing market prices for the Common Shares.

### ***If industry analysts cease to publish research or publish inaccurate or unfavourable research about the Corporation or its business, the Corporation's trading price of its Common Shares or its trading volume could decline***

The trading market for the Common Shares depends in part on the research and reports that industry or securities analysts publish about the Corporation or the Corporation's business. If the Corporation obtains industry or securities analyst coverage and if one or more of the analysts who cover the Corporation downgrade the Common Shares, the trading price of the Common Shares may decline. If one or more of the analysts cease coverage of the Corporation or fails to publish reports on the Corporation regularly, the Corporation could lose visibility in the financial markets, which in turn could cause the Common Share price or trading volume to decline. Moreover, if the Corporation's results of operations do not meet the expectations of the investor community, or one or more of the analysts who cover the Corporation publishes inaccurate or unfavourable research about the Corporation's business, the trading price of the Common Shares may decline.

### ***Maintaining TSXV listing standards***

The Corporation must meet continuing listing standards to maintain the listing of its Common Shares on the TSXV and there is no assurance that it will do so. If the Corporation fails to comply with listing standards the TSXV delists its Common Shares, the Corporation and its shareholders could face significant material adverse consequences, including significantly reduced liquidity for its Common Shares.

As a public company, the Corporation is subject to evolving corporate governance and public disclosure regulations that may from time to time increase both the Corporation's compliance costs and the risk of non-compliance, which could adversely impact the price of the Common Shares.

## **DIVIDENDS**

There are no restrictions in the Corporation's articles or by-laws preventing the Corporation from paying dividends. However, the provisions of the Credit Facility contain certain restrictions and covenants that, subject to certain exceptions, limit the Corporation's ability to pay dividends. In addition, the payment of dividends by the Corporation is governed by the liquidity and insolvency tests described in the OBCA which provides that a corporation shall not declare a dividend if there are reasonable grounds for believing that such corporation is insolvent or the payment of the dividend would render such corporation insolvent.

The Corporation has not declared or paid any dividends since incorporation. The Board anticipates that the Corporation will retain all future earnings and other cash resources for the future operation and development of its business, and accordingly, does not intend to declare or pay any cash dividends in the foreseeable future. Payment of any future dividends will be at the discretion of the Board after taking into account many factors including the Corporation's operating results, financial condition, current and anticipated cash assets and any restrictive covenants under any material credit or commercial agreements.

## **DESCRIPTION OF CAPITAL STRUCTURE**

The Corporation is authorized to issue an unlimited number of Common Shares and an unlimited number of preferred shares, of which 56,154,491 Common Shares are issued and outstanding as fully paid and non-assessable and no preferred shares are issued or outstanding as at the date of this AIF (56,386,518 Common Shares and no preferred shares as of December 31, 2024).

In addition, as at the date of this AIF, there is an aggregate of 10,585,559 Common Shares issuable upon the due exercise of all outstanding Stock Options, warrants and restricted share units of the Corporation (10,646,782 as of December 31, 2024).

### **Description of Common Shares**

Each Common Share carries the right to attend and vote at all general meetings of shareholders. Holders of Common Shares are entitled to receive on a pro rata basis such dividends, if any, as and when declared by the Board at its discretion from funds legally available for the payment of dividends and upon the liquidation, dissolution or winding up of the Corporation are entitled to receive on a pro rata basis the net assets of the Corporation after payment of debts and other liabilities, in each case subject to the rights, privileges, restrictions and conditions attaching to any other series or class of shares ranking senior in priority to or on a pro rata basis with the holders of Common Shares with respect to dividends or liquidation. The Common Shares do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions.

### **Description of Normal Course Issuer Bid**

On November 27, 2024, the Corporation announced the approval by the TSXV of the NCIB to be transacted through the facilities of the TSXV.

Pursuant to the NCIB, the Corporation may, during the 12-month period commencing November 27, 2024 and ending November 26, 2025 (or on such date that the Corporation completes its purchases or provides notice of termination), purchase up to 2,820,044 Common Shares in total, being approximately 5% of the total number of Common Shares outstanding as at November 27, 2024 (being 56,400,893 Common Shares). The price which the Corporation will pay for any such Common Shares will be the prevailing market price at the time of acquisition. Also, in accordance with the policies of the TSXV the Corporation may not purchase more than 2% of its issued and outstanding Common Shares during any 30-day period. The actual number of Common Shares which may be purchased pursuant to the NCIB and the timing of any such purchases, outside of restricted periods, will be determined by management of the Corporation.

Purchases under the NCIB will be made from time to time by Haywood Securities Inc. (“**Haywood**”) on behalf of the Corporation through the facilities of the TSXV or through a Canadian alternative trading system. The Corporation has entered into a pre-defined plan with Haywood to allow for the purchase of Common Shares under the NCIB at times when the Corporation ordinarily would not be permitted to purchase Common Shares due to its internal trading black-out periods, insider trading rules or regulatory restrictions. The plan provides a set of standard instructions to Haywood to make purchases at its sole discretion under the NCIB in accordance with the terms set out in the such plan, the rules of the TSXV and applicable securities laws. Decisions regarding any future repurchases will depend on certain factors, such as market conditions, share price and instructions set forth in the plan. The Corporation may elect to suspend or discontinue share repurchases at any time in accordance with the plan and applicable laws.

As of the date of this AIF, the Corporation had repurchased for cancellation 398,000 Common Shares under the NCIB at a weighted average price of \$0.20.

### **Description of Preferred Shares**

The preferred shares of the Corporation are issuable from time to time in one or more series as determined by the Board. The preferred shares of the Corporation are non-voting and rank senior to the Common Shares with respect to the payment of dividends, the return of capital and the distribution of assets in the event of the liquidation, dissolution or winding-up of the Corporation. The preferred shares of the Corporation do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions.

### **Description of Warrants**

As of the date of this AIF, there are 4,480,000 QT Warrants and 790,138 Broker Warrants issued and outstanding (4,480,000 QT Warrants and 836,111 Broker Warrants as of December 31, 2024).

- (a) QT Warrants: Each QT Warrant entitles the holder thereof to acquire one Common Share, subject to adjustments in certain circumstances, at the price per Common Share set forth in the respective warrant certificates of \$0.25. Each QT Warrant is exercisable by the holder at any time after the date of issuance until January 29, 2026. Each QT Warrant which is not exercised during such period, shall become void and the right to exercise such QT Warrants for Common Shares shall expire and terminate. During the 2024 fiscal year there were no changes to the QT Warrants outstanding.
- (b) Broker Warrants: Each Broker Warrant entitles the holder thereof, subject to adjustments in certain circumstances, to acquire one Common Share at an exercise price of \$0.15 per Common Share until May 2, 2025. Each Broker Warrant which is not exercised during such period, shall become void and the right to exercise such Broker Warrants for Common Shares shall expire and terminate. During the 2024 fiscal year, no Broker Warrants were exercised. In January 2025, 45,973 Broker Warrants were exercised.

### **Description of Stock Options**

The Corporation adopted an amended and restated stock option plan (the “**Stock Option Plan**”) which was approved by shareholders of the Corporation at its Annual General and Special Meeting of Shareholders held on June 22, 2022 and was ratified and confirmed at the Annual General and Special Meeting of Shareholders on June 12, 2024.

The Stock Option Plan is considered a “rolling” plan and pursuant to the policies of the TSXV, will require annual shareholder approval. Pursuant to the Stock Option Plan, the maximum number of Common Shares reserved for issuance is equal to 10% of the number of Common Shares issued and outstanding, on a non-diluted basis, at any time. Notwithstanding the foregoing, the number of Common Shares issued or to be issued under the Stock Option Plan and all other security-based compensation agreements shall not exceed 20% of the total number of issued and outstanding Common Shares, on a non-diluted basis, as at the relevant grant date.

Options to purchase Common Shares of the Corporation (“**Stock Options**”) may not be exercised later than 90 days following the date the optionee ceases to be a director, officer or employee of the Corporation or its affiliates or a consultant or a management company employee, provided that if the cessation of such position or arrangement was

by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such Stock Option.

The Board may, in its discretion, grant any Eligible Person (as defined in the Stock Option Plan) the ability to complete a “cashless exercise” or “net exercise” in accordance with the policies of the TSXV. Additionally, under the Stock Option Plan, any adjustment to the Common Shares issuable under the Stock Option Plan as a result of a subdivision, consolidation, spin-off, merger, acquisition, reclassification or such other capital reorganization will be subject to approval by the TSXV.

As of the date of this AIF, 4,799,171 Stock Options were issued under and governed by the terms of the Stock Option Plan (4,814,421 Stock Options as of December 31, 2024).

The following table sets forth all Stock Options that were issued and outstanding as of the date of this AIF:

<b>Number of Stock Options Outstanding</b>	<b>Exercise Price</b>	<b>Expiry Date</b>
17,992	1.00	April 7, 2025
140,000	1.00	November 30, 2025
127,373	0.87	September 01, 2027
100,000	0.45	May 31, 2027
166,664	0.45	May 31, 2029
465,000	0.30	August 24, 2029
982,500	0.16	November 22, 2029
296,805	0.16	June 15, 2030
1,557,837	0.14	May 30, 2030
120,000	0.18	September 24, 2031
825,000	0.19	December 9, 2031
<b>Total: 4,799,171</b>		

### **Description of Restricted Share Units**

The Corporation adopted an amended restricted share unit plan (the “**RSU Plan**”) which was approved by shareholders of the Corporation at its Annual General and Special Meeting of Shareholders held on June 22, 2022.

Pursuant to the RSU Plan, the Board may grant restricted share units (“**RSUs**”) to directors, officers, employees and consultants of the Corporation, subject to the terms and conditions of the RSU Plan. A maximum of 3,000,000 Common Shares have been reserved for issuance under the RSU Plan. RSUs may be granted by the Board with such vesting conditions (typically based on continued service or achievement of personal or corporate objectives) as the Board may determine in its sole discretion. Each vested RSU may be redeemed for (i) one Common Share, (ii) cash representing the fair market value of such Common Shares on the vesting date or (iii) a combination of (i) and (ii), as determined by the Board in its sole discretion. Certain holders of RSUs may defer the receipt of all or any part of their entitlement to Common Shares and/or cash consideration in lieu of such Common Shares until a later date, in accordance with, and subject to restrictions as further set out in the RSU Plan.

Under the RSU Plan, any adjustment to the Common Shares issuable thereunder as a result of a subdivision, consolidation, spinoff, merger, acquisition, reclassification or such other capital reorganization will be subject to TSXV approval.

As of the date of this AIF, 516,250 RSUs were issued under and governed by the terms of the RSU Plan (516,250 RSUs as of December 31, 2024).

The following table sets forth all of the RSUs that were issued and outstanding as of the date of this AIF:

<u>Number of RSUs Outstanding</u>	<u>Number Vested</u>	<u>Exercise Price</u>	<u>Expiry Date</u>
516,250	Nil	N/A	N/A

### Fully Diluted Share Capital

The number of issued and outstanding Common Shares, Common Share purchase warrants, Stock Options and RSUs on a fully converted basis as at the date of this AIF is as follows:

<u>Type of Security</u>	<u>Number of Common Share equivalents</u>
Common Shares	56,154,491
Common Share purchase warrants	5,270,138
Stock Options	4,799,171
RSUs	516,250
<b>Fully Diluted Common Shares as at March 26, 2025</b>	<b>66,740,050</b>

### Description of Subordinated and Postponed Unsecured Non-convertible Debentures

As part of the Offering completed on May 2, 2023, the Corporation issued 1,453 Units, with each Unit comprising of: (i) \$1,000 principal amount of subordinated and postponed unsecured non-convertible debentures of the Corporation (the “**Debentures**”); and (ii) such number of Common Shares as was equal to 10% of the principal amount of the Debentures purchased divided by \$0.09 (being the market closing price of the Common Shares on the TSXV on April 10, 2023). An aggregate of 1,614,444 Common Shares were issued in connection with the closing of the Offering.

The Debentures were issued pursuant to and are governed by the terms of a debenture indenture dated May 2, 2023 entered into between the Corporation and TSX Trust Company as the debenture trustee. The Debentures will mature on May 2, 2025 and bear interest at a rate of 10% per annum payable quarterly in arrears in cash.

The Corporation is entitled to redeem the Debentures at any time prior to May 2, 2025, in part or in full subject to an early repayment premium equal to: (i) 6% of the principal amount of the Debentures being redeemed, if the redemption occurs prior to a date that is six months following May 2, 2023; (ii) 5% of such principal amount, if redemption occurs following a date that is six months following May 2, 2023, but prior to May 2, 2024; (iii) 4% of such principal amount, if redemption occurs following May 2, 2024, but prior to November 2, 2024; or (iv) 3% of such principal amount, if redemption occurs following November 2, 2024, but prior to the maturity date of May 2, 2025.

On March 26, 2025, the Corporation provided notice to holders of its Debentures of its intention to redeem all outstanding Debentures, being the aggregate amount of \$1,453,000 of Debentures as of the Redemption Date. As a result of the early redemption, the Corporation paid an amount equal to \$1,030 for each \$1000 principal amount of Debentures outstanding, being equal to the aggregate amount of \$1,496,590, plus all accrued and unpaid interest up to, but excluding, the Redemption Date. Proceeds from the 2025 Term Loan that are being used to pay the Total Redemption Price are being held in trust by TSX Trust Company, as debenture trustee, until the Redemption Date. Upon payment of the Total Redemption Price on the Redemption Date, all Debentures redeemed shall be cancelled and the previous holders of Debentures shall have no rights in respect thereof, except to obtain payment of their portion of the Total Redemption Price.

### MARKET FOR SECURITIES

The Corporation’s Common Shares are listed on the TSXV under the trading symbol “NPTH”. Prior to the completion of the Qualifying Transaction, the Common Shares were listed on the TSXV under the trading symbol “KHV.P”. On July 6, 2020, the Common Shares, which were previously halted on March 20, 2020, as a result of the announcement of the Qualifying Transaction, resumed trading on the TSXV under the ticker symbol “NPTH”.

The following table sets out the reported intraday high and low prices and the trading volume for the Common Shares on the TSXV information relating to the trading of the Common Shares during the year ended December 31, 2024.

<b>Month</b>	<b>TSXV Price Range (\$)</b>		<b>Total Volume</b>
	<b>High</b>	<b>Low</b>	
January 2024	0.195	0.17	195,676
February 2024	0.19	0.17	248,050
March 2024	0.195	0.165	1,310,623
April 2024	0.18	0.15	1,208,665
May 2024	0.195	0.17	1,253,005
June 2024	0.225	0.18	985,235
July 2024	0.20	0.16	1,565,565
August 2024	0.205	0.165	993,150
September 2024	0.195	0.16	1,067,411
October 2024	0.17	0.155	2,518,730
November 2024	0.17	0.155	3,483,560
December 2024	0.21	0.165	4,221,579

### **Prior Sales**

During the year ended December 31, 2024, the Corporation did not issue any securities of the Corporation that are outstanding, but not listed or quoted on a marketplace.

### **ESCROWED SECURITIES AND SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER**

To the Corporation's knowledge, there are no Common Shares or other securities of the Corporation that are held in escrow or that are subject to a contractual restriction on transfer as at the date of this AIF. As of December 31, 2024, Common Shares previously held in escrow in connection with the Qualifying Transaction were all released from escrow.

### **DIRECTORS AND OFFICERS**

#### **Name, Occupation and Security Holding**

The following are the names and municipalities of residence of each director and executive officer of the Corporation as of the date of this AIF, the positions and offices to be held with the Corporation, their respective principal occupations within the five preceding years and the number and percentage of common shares of the Corporation which are held by each of them.

Name and city of residence of each Director and Officer	Position held with the Corporation	Principal Occupation for the last five years	Director of the Corporation since	Number and Percentage of Common Shares <sup>(9)</sup>
Daniel Chicoine <sup>(1)</sup> <sup>(4)</sup> <sup>(5)</sup> <i>Port Sydney, Ontario</i>	Director (Chair)	Chair, Crescita Therapeutics Inc., a commercial dermatology company (May 2020 – Present) Director, Nuvo Pharmaceuticals Inc. (September 2004 – March 2023) Executive Chairman, Crescita Therapeutics Inc., (April 2018 – May 2020)	June 25, 2020	98,340 (<0.2%)
Jolyon Burton <sup>(2)</sup> <i>Toronto, Ontario</i>	Director	President and Head of Investment Banking, Bloom Burton Securities Inc., a healthcare sector investment banking firm (2009 – Present)	June 25, 2020	Nil
Sasha Cucuz <sup>(3)</sup> <sup>(6)</sup> <i>North York, Ontario</i>	Director	CEO, Greybrook TMS, a corporate finance and investment banking firm (2005 - Present)	June 25, 2020	53,118 (<0.1%)
Dan Legault <sup>(3)</sup> <sup>(5)</sup> <i>Toronto, Ontario</i>	Director	COO, Juniper Genomics, a genetic testing technology company (2024 - Present) President and CEO, Antibe Therapeutics, a biotechnology company (2009 – 2024)	April 17, 2019	123,118 (<0.3%)
Joseph Walewicz <sup>(7)</sup> <i>Westmount, Quebec</i>	Director and Chief Executive Officer	Chief Executive Officer, NeuPath (October 2022 – Present) Chief Business Officer, NeuPath (July 2022 – September 2022) CFO, Fibrocor Therapeutics Inc., a biotechnology company (January 2021 – March 2022 ) Executive Vice President, Business and Corporate Development, Clementia Pharmaceuticals, a biotechnology company (2017 - 2019)	June 25, 2020	522,194 (<1.0%)
Jeff Zygouras <sup>(8)</sup> <i>Brampton, Ontario</i>	Chief Financial Officer	CFO, NeuPath (July 2021 – Present) Corporate Controller, NeuPath (September 2019 – June 2021)	July 2, 2021	58,150 (<0.1%)

**Notes:**

- (1) Mr. Chicoine was appointed Chair of the Board on October 18, 2022.
- (2) Mr. Burton is the President and Head of Investment Banking of Bloom Burton Securities Inc., which holds, directly and indirectly, 4,425,000 Common Shares, representing approximately 7.9% of the issued and outstanding Common Shares, on a non-diluted basis.
- (3) Member of the Audit Committee.
- (4) Chair of the Audit Committee.
- (5) Member of the Compensation, Nomination and Corporate Governance Committee.
- (6) Chair of the Compensation, Nomination and Corporate Governance Committee.
- (7) Mr. Walewicz was appointed Chief Executive Officer of the Corporation on March 9, 2023. Prior to March 9, 2023, Mr. Walewicz was the Interim Chief Executive Officer effective September 30, 2022 and Chief Business Officer from July 25, 2022 to September 29, 2022.
- (8) Mr. Zygouras was appointed Chief Financial Officer of the Corporation on March 17, 2022. Prior to March 17, 2022, Mr. Zygouras was the Interim Chief Financial Officer effective July 1, 2021 and Corporate Controller from September 4, 2019 to June 30, 2021.
- (9) The percentage is based on 56,154,491 Common Shares issued and outstanding as of the date of this AIF, on a non-diluted basis.



Directors are elected annually and hold office until the Corporation's next annual general meeting of shareholders of the Corporation or until his or her successor is appointed or elected a successor is elected, unless a director's office is earlier vacated in accordance with the by-laws of the Corporation.

As at the date of this AIF, the directors and executive officers of the Corporation, as a group, beneficially owned, directly or indirectly, 854,920 Common Shares constituting approximately 1.5% of the issued and outstanding Common Shares on a non-diluted basis.

### **Cease Trade Orders**

To the knowledge of the Corporation, no director or executive officer of the Corporation is, or within the ten years prior to the date hereof has been, a director, chief executive officer, or chief financial officer, of any company (including the Corporation) that was subject to (a) a cease trade order; (b) an order similar to a cease trade order; or (c) an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than thirty consecutive days, issued while that person was acting in such capacity or issued thereafter, but resulted from an event that occurred while that person was acting in such capacity.

### **Bankruptcies**

To the knowledge of the Corporation, except as disclosed in this AIF, no director or executive officer or shareholder holding a sufficient number of securities of the Corporation to affect materially the control of the Corporation is, or within the ten years prior to the date hereof has been, a director or executive officer of any company (including the Corporation) that, while that person was acting in such capacity or within a year of that person ceasing to act in such capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Dan Legault, director of the Corporation, was the former Chief Executive Officer and Director of Antibe Therapeutics Inc., which was granted creditor protection by the Ontario Superior Court of Justice (Commercial List) pursuant to *Companies' Creditors Arrangement Act* ("CCAA") on April 9, 2024. The court subsequently terminated the CCAA proceeding on April 22, 2024 and appointed a receiver. Dan Legault resigned as Chief Executive Officer and Director of Antibe Therapeutics on April 24, 2024, which subsequently had their shares delisted from the Toronto Stock Exchange on May 24, 2024.

To the knowledge of the Corporation, no director or executive officer or shareholder holding a sufficient number of securities of the Corporation to affect materially the control of the Corporation has, within the ten years prior to the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement, or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold that person's assets.

### **Penalties and Sanctions**

No director or executive officer of the Corporation, or a shareholder holding a sufficient number of securities of the Corporation to affect materially the control of the Corporation has been subject to (a) any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or (b) any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

All of the above disclosure also applies to any personal holding companies of any of the persons referred to above.

### **Conflicts of Interest**

Directors and officers of the Corporation may also serve as directors and/or officers of, or otherwise be involved with or consulted by, other companies engaged in the health services industry and may be presented from time to time with situations or opportunities which give rise to apparent conflicts of interest which cannot be resolved by arm's length negotiations, but only through exercise by the officers and directors of such judgment as is consistent with their

fiduciary duties to the Corporation which arise under applicable corporate law, especially insofar as taking advantage, directly or indirectly, of information or opportunities acquired in their capacities as directors or officers of the Corporation. It is expected that all conflicts of interest will be resolved in accordance with the OBCA, the Corporation's by-laws and internal governance policies. It is expected that any transactions with officers and directors of the Corporation will be on terms consistent with industry standards and sound business practice in accordance with the fiduciary duties of those persons to the Corporation, and, depending upon the magnitude of the transactions and the absence of any disinterested board members, may be submitted to the shareholders for their approval. As of December 31, 2024, there are no existing or potential material conflicts of interest the Corporation and any of the directors and/or officers of the Corporation.

### **LEGAL PROCEEDINGS AND REGULATORY ACTIONS**

There are no material legal proceedings or regulatory actions to which the Corporation or a subsidiary of the Corporation is a party or of which any of their respective property is the subject matter and no such material legal proceedings or regulatory action known to the Corporation are contemplated.

### **INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS**

Except as provided herein, there are no material interests, direct or indirect, of directors, executive officers, any shareholders who beneficially own, or controls or directs, directly or indirectly, more than 10% of the Common Shares, or any known associates or affiliates of such persons, in any transaction within the last three completed financial years or during the current financial year which has materially affected or is reasonably expected to materially affect the Corporation.

### **INTEREST OF EXPERTS**

There is no person or company whose profession or business gives authority to a statement made by such person or company and who is named as having prepared or certified a statement, report or valuation described or included in a filing, or referred to in a filing, made under NI 51-102 by the Corporation other than Ernst & Young LLP, Chartered Professional Accountants, the Corporation's auditor. The Corporation's consolidated financial statements as at December 31, 2024 and 2023 have been audited by Ernst & Young LLP, as indicated in their report dated March 26, 2024. Ernst & Young LLP has been the Corporation's auditors since August 13, 2020.

Ernst & Young LLP has advised that they are independent with respect to the Corporation within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Ontario (registered name of the Institute of Chartered Accountants of Ontario).

### **TRANSFER AGENT**

TSX Trust Company, at its principal office in Toronto, Ontario, is the transfer agent and registrar for the Common Shares.

### **MATERIAL CONTRACTS**

There are no material contracts required to be disclosed that have been entered into by the Corporation within the most recently completed fiscal year or before the most recently completed fiscal year, but still in effect other than contracts entered into in the ordinary course of business not otherwise required to be disclosed.

### **AUDIT COMMITTEE INFORMATION**

#### **The Audit Committee's Charter**

The full text of the Corporation's Audit Committee Charter is appended hereto as Appendix "A".

## **Composition of the Audit Committee and Relevant Education and Experience**

The members of the Audit Committee are Daniel Chicoine (Chair), Dan Legault and Sasha Cucuz. All the members of the Audit Committee are independent and financially literate in accordance with National Instrument 52-110 – *Audit Committees*. A brief summary of each member’s relevant education and experience is provided below.

Daniel Chicoine is currently the Chair of Crescita Therapeutics Inc. (TSX:CTX). From April 3, 2018 to May 10, 2021, Mr. Chicoine served as Crescita’s Executive Chairman. From March 1, 2016 until April 2, 2018, Mr. Chicoine served as Crescita’s Chairman and Interim Chief Executive Officer. Mr. Chicoine served as Nuvo Research’s Chairman and Co-CEO and was actively involved in its day-to-day operations from 2004 to 2016 when Crescita became a reporting issuer following the reorganization of Nuvo Research into two separate publicly traded entities, Crescita and Nuvo Pharmaceuticals Inc. Prior to 2004, Mr. Chicoine held various senior executive positions at the Magna International group of companies, including President and Chief Executive Officer of the Interiors group and Chief Financial Officer of their Body and Chassis group and was the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.

Dan Legault is currently the Chief Operating Officer of Juniper Genomics. From 2009 to 2024, Mr Legault served as the Chief Executive Officer of Antibe Therapeutics (TSXV:ATE). Trained as a corporate lawyer and as an air force rescue pilot, Mr. Legault’s career has evolved to focus on high-growth, mostly technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing. Mr. Legault has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. Mr. Legault continues to serve as a board member and advisor to several companies and not-for-profit organizations. Mr. Legault is a member of the Law Society of Upper Canada and the New York State Bar.

Sasha Cucuz is the Chief Executive Officer of Greybrook Securities, Inc. since 2005, where he directs Greybrook’s capital markets activities across the firm’s focus areas in real estate and healthcare. Operationally, Mr. Cucuz co-manages Greybrook Realty Partners’ business across both its Asset Management and Capital Markets verticals. Mr. Cucuz also serves as the Co-chair of Greybrook’s Advisory Committee for all active limited partnerships which include more than 50 real estate developments with an estimated completion value of approximately \$14 billion, and as the Co-chair of Greybrook’s investment committee. As the former CEO of Greybrook Health, Mr. Cucuz played a critical role in the launch of Greenbrook TMS and Greybrook’s prior portfolio acquisitions of MacuHealth and Bruder Health Care. He currently serves on the board of Greenbrook TMS, as well as on the boards of a number of Greybrook affiliated companies and the Blu Genes Foundation. After receiving a Bachelor of Arts in Economics from York University in 2000, Sasha went on to play professional hockey for three seasons. Mr. Cucuz began his career at TD Securities and CIBC before founding Greybrook Capital with his partners.

## **Audit Committee Oversight**

The Audit Committee oversees the accounting and financial reporting practices and procedures of the Corporation and the audits of the Corporation’s financial statements. The principal responsibilities of the Audit Committee include: (i) overseeing the quality and integrity of the internal controls and accounting procedures of the Corporation, including reviewing the Corporation’s procedures for internal control with the Corporation’s auditor and Chief Financial Officer; (ii) reviewing and assessing the quality and integrity of the Corporation’s annual and quarterly financial statements and related management discussion and analysis, as well as all other material continuous disclosure documents, such as the Corporation’s annual information form; (iii) monitoring compliance with legal and regulatory requirements related to financial reporting; (iv) reviewing and approving the engagement of the auditor of the Corporation and independent audit fees; (v) reviewing the qualifications, performance and independence of the auditor of the Corporation, considering the auditor’s recommendations and managing the relationship with the auditor, including meeting with the auditor as required in connection with the audit services provided to the Corporation; (vi) assessing the Corporation’s financial and accounting personnel; (vii) reviewing the Corporation’s risk management procedures; (viii) reviewing any significant transactions outside the Corporation’s ordinary course of business and any pending litigation involving the Corporation; and (ix) examining improprieties or suspected improprieties with respect to accounting and other matters that affect financial reporting.

## Pre-Approval Policies and Procedures

The Audit Committee has adopted policies and procedures with respect to the pre-approval of permitted non-audit services by Ernst & Young LLP. The Audit Committee has established a budget for the provision of a specified list of permitted non-audit services that the Audit Committee believes to be typical, recurring or otherwise likely to be provided by Ernst & Young LLP. The budget generally covers the period between the adoption of the budget and the next meeting of the Audit Committee, but at the option of the Audit Committee it may cover a longer or shorter period. The list of services is sufficiently detailed as to the particular services to be provided to ensure that: (i) the Audit Committee knows precisely what services it is being asked to pre-approve; and (ii) it is not necessary for any member of management to make a judgment as to whether a proposed service fits within the pre-approved services.

The Audit Committee has delegated authority to the Chair of the Audit Committee (or if the Chair is unavailable, any other member of the Audit Committee) to pre-approve the provision of permitted non-audit services by Ernst & Young LLP that have not otherwise been pre-approved by the Audit Committee, including the fees and terms of the proposed services (“**Delegated Authority**”). All pre-approvals granted pursuant to Delegated Authority must be presented by the member(s) who granted the pre-approvals to the full Audit Committee at its next meeting. All proposed services, or the fees payable in connection with such permitted non-audit services, that have not already been pre-approved must be pre-approved by either the Audit Committee or pursuant to Delegated Authority. Prohibited services may not be pre-approved by the Audit Committee or pursuant to Delegated Authority.

## External Auditors Service Fees (By Category)

The aggregate fees billed and accrued by the Corporation’s external auditors, Ernst & Young LLP., in the last two fiscal years for auditor service fees were as follows:

<u>Financial Year Ending</u>	<u>Audit Fees</u>	<u>Audit Related Fees</u>	<u>Tax Fees</u>	<u>All Other Fees</u>
<u>December 31, 2024</u>	<u>326,000</u>	<u>-</u>	<u>-</u>	<u>-</u>
<u>December 31, 2023</u>	<u>395,000</u>	<u>-</u>	<u>-</u>	<u>-</u>

## ADDITIONAL INFORMATION

Additional information about the Corporation may be found under the Corporation’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca). Additional information, including directors’ and officers’ remuneration and indebtedness, principal holders of the Corporation’s securities, options to purchase securities and securities authorized for issuance under the Corporation’s equity compensation plans, is contained in the Corporation’s management information circular for its most recent annual meeting of shareholders. Additional information may also be found in the Corporation’s audited financial statements and related management’s discussion and analysis for the year ended December 31, 2024.

## APPENDIX A



NEUPATH HEALTH INC.

### AUDIT COMMITTEE CHARTER

---

#### 1. PURPOSE

The audit committee (the “**Committee**”) has been established by resolution of the board of directors (the “**Board**”) of NeuPath Health Inc. (the “**Corporation**”) for the purpose of assisting the Board in fulfilling its oversight responsibilities in relation to the accounting and financial reporting processes of the Corporation, audits of the financial statements of the Corporation, review of the Corporation’s systems of internal controls and in relation to risk management matters including:

- (a) the review of the annual and interim financial statements of the Corporation;
- (b) the integrity and quality of the Corporation’s financial reporting and systems of internal control, and financial risk management;
- (c) the Corporation’s compliance with legal and regulatory requirements;
- (d) the qualifications, independence, engagement, compensation and performance of the Corporation’s external auditor (the “**Corporation’s Auditor**”); and
- (e) the exercise of the responsibilities and duties set out in this charter (the “**Charter**”).

#### 2. COMPOSITION

The members of the Committee shall be appointed by the Board from amongst the directors of the Corporation (the “**Directors**”) and shall be comprised of not less than three members. All of the members of the Committee shall be “independent”, as such term is defined in National Instrument 52-110 – *Audit Committees* (“**NI 52-110**”).

All members of the Committee shall be “financially literate”, as such term is defined in NI 52-110 or shall acquire within a reasonable time following appointment to the Committee, the ability to read and understand a set of financial statements that present the breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation’s financial statements.

Members of the Committee and the chairperson of the Committee (the “**Chair**”) will be appointed or re-appointed annually by the Board, on the recommendation of the compensation, nominating and corporate governance committee (the “**CNCG Committee**”), at the first meeting of the Board after the annual general meeting of shareholders at which he or she is elected. Any member of the Committee may be removed or replaced at any time by the Board and will serve until such member’s successor is appointed, unless that member resigns or otherwise ceases to be a director of the Corporation. The Board will immediately fill any vacancy if the membership of the

Committee is less than three directors. If and whenever a vacancy will exist, the remaining members of the Committee may exercise all of its powers and responsibilities so long as a quorum remains in office.

No Director who serves as board member of any other corporation shall be eligible to serve as a member of the Committee unless the Board has determined that such simultaneous service would not impair the ability of such member to effectively serve on the Committee. Determinations as to whether a particular Director satisfies the requirements for membership on the Committee shall be made by the CNCG Committee. No member of the Committee shall receive from the Corporation or any of its affiliates any compensation other than the fees to which he or she is entitled as a Director of the Corporation or a member of a committee of the Board. Such fees may be paid in cash and/or shares, options or other in-kind consideration ordinarily available to Directors.

### **3. MEETING PROTOCOLS**

The Committee shall meet at least once every quarter and shall meet at such other times during each year as the Chair deems appropriate. The Chair, any member of the Committee, the Corporation's Auditor, the Chairman of the Board, the Chief Executive Officer of the Corporation ("CEO") or the Chief Financial Officer of the Corporation ("CFO") may call a meeting of the Committee by notifying the Corporation's corporate secretary, who will notify the members of the Committee. If the Chair is not present at any meeting of the Committee, one of the other members of the Committee who is present at the meeting shall be chosen by the Committee to preside at the meeting. A majority of members of the Committee shall constitute a quorum.

At least five days' notice of any meeting of the Committee shall be given in writing to each member of the Committee by any means of transmitted or recorded communication that produces a written copy, including by email. Notice may be waived or shortened with the consent of all the members of the Committee. Attendance by a member at a meeting notwithstanding any failure to give notice in accordance with this Charter shall be deemed to constitute waiver of notice of such meeting by such member. Notice of each meeting of the Committee shall also be given to the Chairman of the Board, the CEO, the CFO, and, as applicable, to the Corporation's Auditor.

The Chairman of the Board, the CEO and the CFO, if invited by the Chair, attend and speak at meetings of the Committee. Other Board members shall also, if invited by the Chair have the right of attendance. A representative of the Corporation's Auditor shall have the right to attend and speak at any meeting of the Committee, and may attend if invited by the Chair, in either case at the expense of the Corporation.

The Committee may also invite any other officers or employees of the Corporation, legal counsel, the Corporation's financial advisors and any other persons to attend meetings and give presentations with respect to their area of responsibility, as considered necessary by the Committee.

At quarterly meetings where the Auditors are in attendance, representatives of the Corporation's Auditor shall meet the Committee without any of the executive Directors or other members of management in attendance, except by invitation of the Committee.

The Committee shall at each meeting appoint one of its members or any other attendee to be the secretary of the Committee.

Every question at a Committee meeting shall, if necessary, be decided by a majority of the votes cast.

Subject to any statutory or regulatory requirements or the articles and by-laws of the Corporation, the Committee shall fix its own procedures at meetings, maintain minutes or other records of its proceedings in sufficient detail to convey the substance of all discussions held and report to the Board at the next meeting of the Board. The minutes of the Committee's meetings shall be tabled at the next meeting of the Board.

The Committee shall prepare a report to shareholders or others, concerning the Committee's activities in the discharge of its responsibilities, when and as required by the by-laws of the Corporation or applicable laws or regulations.

#### 4. AUTHORITY

The Committee is authorized by the Board to:

- (a) investigate any matter within its Charter;
- (b) have direct communication with the Corporation's Auditor;
- (c) seek any information it requires from any employee of the Corporation; and
- (d) retain, at its discretion, outside legal counsel, or accounting or other advisors, at the expense of the Corporation, to obtain advice and assistance in respect of any matters relating to its duties, responsibilities and powers as provided for or imposed by this Charter or otherwise by law or the by-laws of the Corporation.

#### 5. ROLES AND RESPONSIBILITIES

The Committee shall have the roles and responsibilities set out below, as well as any other functions that are specifically delegated to the Committee by the Board and that the Board is authorized to delegate by applicable laws and regulations. In addition to these roles and responsibilities, the Committee shall perform the duties required of an audit committee by any exchange upon which securities of the Corporation are traded, or any governmental or regulatory body exercising authority over the Corporation.

(a) Review of Accounting and Financial Reporting Matters

1. Review the Corporation's interim and annual financial statements and management's discussion & analysis of operations (the "MD&A"); annual information forms and earnings press releases prior to their public disclosure and Board approval, where required, and ensure that adequate procedures are in place for the review of the Corporation's public disclosure of financial information extracted or derived from the Corporation's financial statements.
2. Following such review with management and the Corporation's Auditor, recommend to the Board whether to approve the annual or interim financial statements and MD&A and any other filings with the applicable securities commissions.
3. Monitor, in discussion with the Corporation's Auditor, the integrity of the financial statements of the Corporation before submission to the Board, focusing particularly on, among other things:
  - A. significant accounting policies and practices and any changes in such accounting policies and practices;
  - B. major judgment areas including significant estimates and key assumptions;
  - C. significant adjustments resulting from the audit;
  - D. the going concern assumption;
  - E. compliance with accounting standards including the effects on the financial statements of alternative methods within generally accepted accounting principles;
  - F. the Corporation's Auditor's judgment about the quality, not just the acceptability, of the accounting principles applied in the Corporation's financial reporting;
  - G. compliance with stock exchange and legal requirements;
  - H. the extent to which the financial statements are affected by any unusual transactions;

- I. significant off-balance sheet and contingent asset and liabilities and the related disclosures;
  - J. significant interim review audit findings during the year, including the status of previous audit recommendations; and
  - K. all related party transactions with the required disclosures in the financial statements.
4. On at least an annual basis, review with the Corporation's legal counsel and management, all legal and regulatory matters and litigation, claims or contingencies, including tax assessments, that could have a material effect upon the financial position of the Corporation, and the manner in which these matters may be, or have been, disclosed in the financial statements.

(b) Relationship with the Corporation's Auditor

- 1. Consider and make recommendations to the Board, for it to put to the shareholders for their approval in a general or special meeting, in relation to the appointment, re-appointment and removal of the Corporation's Auditor and to approve the compensation and terms of engagement of the Corporation's Auditor for the annual audit, interim reviews and any other audit related services.
- 2. Require the Corporation's Auditor to report directly to the Committee.
- 3. Discuss with the Corporation's Auditor, before an audit commences, the nature and scope of the audit, and other relevant matters.
- 4. Review and monitor the independence, objectivity and performance of the Corporation's Auditor and the effectiveness of the audit process taking into consideration relevant professional and regulatory requirements.
- 5. Review and approve the Corporation's hiring policies regarding partners, employees and former partners and employees of the present and former auditor of the Corporation.
- 6. Discuss problems and reservations arising from an audit, and any matters the Corporation's Auditor may wish to discuss (in the absence of management where necessary).
- 7. Review the Corporation's Auditor's management letter and management's response.
- 8. Develop and implement a pre-approval policy on the engagement of the Corporation's Auditor to supply non-audit services to the Corporation and its subsidiaries, taking into account relevant ethical guidance regarding the provision of non-audit services by the Corporation's Auditor and the preservation of their independence.
- 9. Consider the major findings of the Corporation's Auditor and management's response, including the resolution of disagreements between management and the Corporation's Auditor regarding financial reporting.

(c) Review of Disclosure Controls & Procedures ("DC&P") and Internal Controls Over Financial Reporting ("ICFR")

- 1. Monitor and review the Corporation's Disclosure Policy on an annual basis.
- 2. In conjunction with each fiscal year end, review management's assessment of the design and effectiveness of Corporation's DC&P including any control deficiencies identified and the related remediation plans for any significant or material deficiencies.



3. In conjunction with each fiscal year end, review management's assessment of the design and effectiveness of the Corporation's ICFR including any control deficiencies identified and the related remediation plans for any significant or material deficiencies.
4. Review and discuss any fraud or alleged fraud involving management or other employees who have a role in the Corporation's ICFR and the related corrective and disciplinary action to be taken.
5. Discuss with management any significant changes in the ICFR that are disclosed, or considered for disclosure, in the MD&A, on a quarterly basis.
6. Review and discuss with the CEO and the CFO the procedures undertaken in connection with CEO and CFO certifications for the annual and interim filings with the securities commissions.
7. Review the adequacy of internal controls and procedures related to any corporate transactions in which directors or officers of the Corporation have a personal interest, including the expense accounts of senior officers of the Corporation and officers' use of corporate assets.

(d) Review of the Corporation's Financing and Insurance

1. Review the adequacy of the Corporation's insurance policies.
2. Review all major financings of the Corporation and its subsidiaries and annually review the Corporation's financing plans and strategies.

(e) Financial Risk Management

1. Review with the CEO and CFO and the Corporation's Auditor their assessment of the significant financial risks and exposures of the Corporation and discuss with management the steps which the Corporation has taken to monitor and control such exposures.
2. Review current and expected future compliance with covenants under any financing agreements.
3. Review any other significant financial exposures including such things as tax audits, government audits or any other activities that expose the Corporation to the risk of a material financial loss.
4. Report the results of such reviews to the Board for the purpose of assisting the Board in identifying the principal business risks associated with the businesses of the Corporation.

(f) Establishment of Procedures for the Receipt and Treatment of Complaints regarding Accounting, Internal Accounting Controls, or Auditing Matters

Establish procedures for:

- A. the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls, or auditing matters;
- B. the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters; and
- C. the investigation of such matters with appropriate follow-up action.

(g) Corporate Governance

The Committee may, if requested:

- A. review the appropriateness and effectiveness of the Corporation's policies and business practices which impact on the financial integrity of the Corporation, including those relating to insurance, accounting, management reporting and risk management; and
- B. review with management and the external auditor their assessment of the significant financial risks and exposures of the Corporation and discuss with management the steps which the Corporation has taken to monitor and control such exposures.

(h) Complaints and Employee Submissions

The Committee shall establish procedures for:

- A. the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls, or auditing matters; and
- B. the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters.

## **6. COMMITTEE EFFECTIVENESS PROCEDURES**

The Committee shall review its Charter on an annual basis, or more often as required, to ensure that they remain adequate and relevant, and incorporate any material changes in statutory and regulatory requirements and the Corporation's business environment.

The procedures outlined in this Charter are meant to serve as guidelines, and the Committee may adopt such different or additional procedures as it deems necessary from time to time.

In setting the agenda for a meeting, the Chair shall encourage the Committee members, management, the Corporation's Auditor and other members of the Board to provide input in order to address emerging issues.

Prior to the beginning of a fiscal year, the Committee shall submit an annual planner for the meetings to be held during the upcoming fiscal year, for review and approval by the Board to ensure compliance with the requirements of the Committee's Charter.

Any written material provided to the Committee shall be appropriately balanced (i.e. relevant and concise) and shall be distributed at least five business days in advance of the respective meeting to allow Committee members sufficient time to review and understand the information.

The Committee shall conduct an annual self-assessment of its performance and this Charter, and shall make recommendations to the Board with respect thereto.

Members of the Committee shall be provided with appropriate and timely training to enhance their understanding of auditing, accounting, regulatory and industry issues applicable to the Corporation.

New Committee members shall be provided with an orientation program to educate them on the Corporation, their responsibilities and the Corporation's financial reporting and accounting practices.

**7. CHARTER REVIEW**

The Committee shall review and assess the adequacy of this Charter annually and recommend to the Board any changes it deems appropriate.

**8. CURRENCY OF THIS CHARTER**

The Board adopted this Charter on May 15, 2020 and amended this Charter on October 30, 2020.